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Chapter 1
Introduction and outline of thesis
2GENERAL INTRODUCTION
While compared to other cancers primary brain tumours are relatively rare in adults, 
they constitute the most common paediatric solid tumours in children with an incidence 
of 1.7-4,1/100,000 [1,2]. Primary brain tumours are the leading cause of cancer 
related death in children under 16 years of age [1,2]. The significant improvements 
in survival as seen in children with haematological cancers such as leukaemia have 
not been achieved for most of the malignant central nervous system (CNS) tumours. 
The pathologic spectrum, distribution, and behaviour of paediatric CNS tumours differ 
considerably from the adult group of CNS tumours. The treatment of CNS tumours 
in children provides tremendous challenges because of the need to preserve the 
mental and physical development of the child. Apart from the astroglial tumours, these 
paediatric tumours are medulloblastomas (MBs) and ependymal tumours (ETs), which 
are both neuroepithelial tumours [3].
The majority of MBs occur in individuals younger than 16 years, with a mean age 
of 9 years, accounting for 15-30% of all intracranial tumours in this group [4]. The 
incidence in children is 5.5-7.0 per million [5,6]. The male to female ratio is 1.6:1 [4]. 
MBs were initially described by Bailey and Cushing in 1925 as tumours consisting 
of small, undifferentiated, round cells arising in the wall of the fourth ventricle and 
projecting into the centre of the cerebellum [7]. Similar tumours were described in 
adults in other sites of the brain and later classified as primitive neuroectodermal 
tumours (PNETs). MBs might be referred to as ‘posterior fossa PNETs’ [8]. The World 
Health Organisation (WHO) definition of MB is ‘a malignant, invasive embryonal 
tumour of the cerebellum with preferential manifestation in children, predominantly 
neuronal differentiation, and an inherent tendency to metastasise via cerebrospinal 
fluid (CSF) pathways’ [8].
ETs account for 6 to 12% of primary intracranial tumours in children and 1-3% of 
primary intracranial tumours in adults. Thirty percent of children affected are younger 
than 3 years old [9]. The incidence of ETs in children and adolescents is estimated to 
be 1.9 per million and are equally distributed over the two sexes [10]. ETs were first 
described in the 19th century by Virchow and in 1924 classified by Bailey and Cushing 
as glial tumours [11]. The WHO definition is ‘a tumour predominantly composed of 
neoplastic ependymal cells, with preferential manifestation in children and young 
adults’ [12].
3MEDULLOBLASTOMAS
Clinical symptoms, diagnosis and treatment
Clinical symptoms usually occur when medulloblastomas (MBs) grow into or 
compress the fourth ventricle, with subsequent obstruction of the CSF flow, resulting 
in increased intracranial pressure. This obstruction, rather than the tumour itself, 
causes headache, lethargy, papilloedema, nausea and vomiting. Ataxia, nystagmus 
and 6th cranial nerve palsy develop as a result of direct infiltration of brainstem by MB, 
subarachnoid spread of tumour to the sixth nerve, or a diffuse increase in intracranial 
pressure. If the tumour invades the meninges at the level of the foramen magnum, 
or if there is cerebellar tonsil herniation from increased intracranial pressure, nuchal 
rigidity and a headtilt may result. Very young children with open sutures may have 
non-specific signs such as anorexia, failure to thrive and increased head size [13]. 
Symptoms caused by extraneural metastasis are seen in 7% of cases. Most of these 
metastases (88%) are found in bones and cause local pain [14,15].
The current procedure of radiological imaging is magnetic resonance imaging 
(MRI) using both T1-weighted images with and without contrast, and T2-weighted 
images. MBs demonstrate a well-demarcated hypointense signal on T1-weighted 
images with contrast enhancement and a hyperintense signal on T2-weighted 
images [16]. Leptomeningeal involvement can be diagnosed with a high degree of 
certainty on MRI. CSF cytology may be useful when the MRI is equivocal for the 
presence of leptomeningeal metastasis. Spinal MRI is relevant for staging of disease 
postoperatively according to criteria developed by Chang et al. (Table 1) [17].
Most MBs originate in the wall of the fourth ventricle. Although the cell of origin of 
these tumours is controversial, it is probable that MB takes its origin from germinative 
neuroepithelial cells in the roof of the 4th ventricle [3]. They appear macroscopically 
as soft grey-pink masses, often with local necrosis. Four MB subtypes are described 
in the WHO 2000 classification: Large cell/ anaplastic MBs, classic MBs, desmoplastic 
MBs, and MBs with extensive nodularity and advanced neuronal differentiation. Large 
cell/ anaplastic MBs are characterised by large, round and pleomorphic nuclei with 
prominent nucleoli and an abundant cytoplasm [8]. Classic MBs are composed of small 
densely packed cells with round-to-oval highly hyperchromatic nuclei surrounded by 
scanty cytoplasm [8]. The histological hallmark of desmoplastic MBs is the presence 
of nodules or pale islands, which are comprised of clusters of cells with round, 
regular nuclei and abundant, fibrillar cytoplasm [18]. MBs with extensive nodularity 
and advanced neuronal differentiation show intranodular nuclear uniformity and cell 
streaming in a fibrillary background.
Stage Description
T stage 
T1 Tumour less than 3 cm in diameter and limited to the midline position in the vermis, 
the roof of the fourth ventricle and less frequently cerebellar hemispheres
T2 Tumour more than 3 cm in diameter, further invading one adjacent structure or 
partially filling the fourth ventricle
T3a Tumour invading two adjacent structures or completely filling the fourth ventricle 
with extension into the aqueduct of Sylvius, foramen of Magendie or foramen of 
Luschka, thus producing marked internal hydrocephalus
T3b Tumour arising from the floor of the fourth ventricle or brain stem and filling the 
fourth ventricle
T4 Tumour further spreading through the aqueduct of Sylvius to involve the third 
ventricle or midbrain or tumour extending to the upper cervical cord
M stage 
M0 No evidence of gross subarachnoid or haematogenous metastasis
M1 Microscopic tumour cells found in cerebrospinal fluid
M2 Gross nodule seedings demonstrated in the cerebellar, cerebral subarachnoid 
space or in the third or lateral ventricles
M3 Gross nodule seedings in the spinal subarachnoid space 
M4 Extraneuroaxial metastasis
Table 1 Chang staging system for posterior fossa medulloblastoma [17].
No formal grading system of MBs has evolved and treatments are currently not 
stratified by histological grade [18,19]. Large cell/ anaplastic MBs are associated with 
aggressive behaviour, in casu CSF dissemination and extracranial metastases [20]. 
MBs with extensive nodularity and advanced neuronal differentiation have a better 
prognosis than the other histopathological variants. In a study of 330 MBs from the 
US Pediatric Oncology Group, increasing grade of anaplasia and extent of anaplasia 
were associated with aggressive clinical behaviour. Neither degree of nodularity nor 
desmoplasia were associated with longer survival [18].
The most common cytogenetic abnormality described in MBs is a deletion of 17p, 
alone or in combination with an isochromosome 17q, found in approximately 30% of 
tumours. Chromosome 17p possibly harbours a tumour suppressor gene [21]. The 
5clinical relevance of loss of 17p is unclear. Some retrospective reviews in the literature 
correlated loss of 17p with a poor outcome, whereas others did not find this association 
[21-24]. Loss of heterozygosity (LOH) studies trying to link loss of heterozygosity on 
17p and adverse prognosis gave contradictionary findings [21,23,24].
Comparative genomic hybridisation (CGH) studies failed to identify specific genetic 
abnormalities or patterns associated with prognosis. An array of non-random genomic 
losses is found [25]. Repeated chromosomal imbalances most frequently involve 
chromosome 17 (loss of 17p and gain of 17q) and losses of chromosomes 10q, 11 and 
8. In a study investigating 77 cases of MBs, all four patients with MYCC amplification 
died within months of diagnosis, compared with 50% of patients whose tumour did 
not show MYCC amplification [26]. However, in another study an association between 
MYCC and MYCN expression and prognosis was absent [27].
Combining clinical factors with tumour ERBB2 (epidermal growth factor receptor) 
expression (assessed by Western Blot) might allow a more accurate prediction. A recent 
study showed that all 26 children with ERBB2-negative disease were alive 5 years after 
diagnosis, against only 54% of children with ERBB2-positive tumours (p < 0.0001) [27]. 
Tumour DNA ploidy has been variably associated with outcome, and is not incorporated 
into prospective staging systems [28].
Therapeutic approaches are based on separation of patients into ‘average-risk’ and 
‘high-risk’ categories. ‘Average-risk’ patients are those who are 3 years of age or 
older, with a total or near total resection and no evidence of tumour spread beyond 
the primary tumour site. ‘High-risk’ patients are younger than 3 years of age, with 
more than 1.5 cm2 residual tumour after surgery and/ or spread of tumour outside 
the primary site [29]. The extent of the disease at the time of diagnosis is the most 
significant prognostic factor. In children with localised disease, the amount of residual 
disease present after surgery is the most important prognostic factor. The probable 
explanation for the poorer survival of children less than 3 years of age is that they 
receive a lower therapeutic radiation therapy (RT) dose rather than that their tumours 
possess different biologic characteristics [29]. 
In all patients, surgery is the initial step in treatment of MBs. The aim is gross total 
resection, which is attainable in approximately 75% of patients. A retrospective 
study demonstrated that gross total surgical resection results in an improved overall 
progression-free survival rate in patients with non-disseminated tumours [30]. After 
surgery, 10-20% of children suffer from ‘cerebellar-mutism syndrome’, a poorly 
understood combination of mutism, ataxia, personality change and cranial nerve 
deficits, following surgery. This syndrome is not related to the extent of resection. 
The cerebellum is probably involved in the mental initiation preceding any intentional 
bucco-phonatory movements. Median duration in a group of 8 affected children was 4 
weeks. Recovery was near complete for all children [31].
6For patients older than 3 years, surgery is always followed by craniospinal RT with a 
boost to the primary tumour site [29]. For ‘average-risk’ patients, the standard dose of 
craniospinal irradiation is 35-36 Gy (in fractions of 1,5-1,8 Gy, 5 times per week) plus 
an additional 18-20 Gy boost in 18 fractions to the posterior fossa [32-36]. In children 
aged 1.5-2.9 years, a reduced-dose RT of 45 Gy to the primary tumour and 23.4 Gy to 
the craniospinal axis is given [29]. Craniospinal irradiation reduces dissemination and 
improves outcome: the progression-free survival rate at 5 years in patients receiving 
local RT only is about 10%, whereas it is 50% in those children receiving craniospinal 
axis irradiation with local boost. The best survival rates have been reported for patients 
who received RT immediately following surgery [32-36].
Recent trials suggest that all patients should be treated with adjuvant chemotherapy 
(ChT) [29,32,35]. The addition of ChT improves event-free survival at 3 and 5 years 
[35]. Packer et al. treated 65 children with ‘average-risk’ MBs between 3 and 10 years 
of age, with reduced-dose craniospinal RT and adjuvant vincristine, lomustine, and 
cisplatin ChT. Progression-free survival was 86% +/- 4% at 3 years and 79% +/- 7% 
at 5 years. Sites of relapse for the 14 patients who developed progressive disease 
included the local tumour site alone in two patients, local tumour site and disseminated 
disease in nine, and non-primary sites alone in three. The overall survival rates 
compared favourably to those obtained in studies using full-dose RT alone or full 
dose RT plus ChT, suggesting that reduced-dose craniospinal RT and adjuvant ChT 
is a feasible approach for ‘average-risk’ children [34]. For this group of children, the 
combination of vincristine, cisplatin, and lomustine is considered the best choice of 
ChT [34]. A potential advantage of ChT is reduction of the total radiation dose without 
impairment of local control and curation rate, thereby reducing the long-term effects 
of RT on neuropsychologic and endocrine development.
For patients with ‘high-risk’ disease, recent clinical trials have focussed on intensifying 
ChT, including high-dose chemotherapy with autologous peripheral stem cell support 
[37]. In children younger than 3 years, the use of ChT has been investigated in 
an attempt to spare the developing brain from late adverse neurocognitive and 
neuroendocriene late sequelae due to RT. Craniospinal RT will result in significant 
intellectual deterioration in these children, with reductions in IQ of up to 40 points 
[32,38]. However, without RT, survival rates are disappointing. In a study of 35 children 
younger than 3 years who were treated with conventional ChT and without RT, 20 
(57%) relapsed at a median time of 6.3 months [39].
In case of relapse after RT, the outcome is very poor. The vast majority dies within 18 
months of relapse [21]. No standard therapy is available. In a study using high-dose 
thiotepa and etoposide with autologous bone marrow rescue, a partial response was 
observed in 2 of the 6 (33%) patients 28 days following the autologous bone marrow 
rescue [40].
Due to significant advances in surgical techniques, RT, and the introduction of ChT 
regimens, survival rates for children with MBs have improved in recent years [29,35]. 
7Nowadays, a recurrence-free 5-year survival can be achieved in 60-65% of the patients 
[3,29,32,35]. Long-term survivors face life long sequelae from combined treatment, 
impairing their quality of life [32]. As RT and ChT impair the hypothalamic functions, 
endocrinopathy is common, with growth hormone deficiency in 75-85% and thyroid 
abnormalities in 35-69% of cases, resulting in the need for life long substitution [41-
42]. The adverse effects of RT on neuropsychological status increase with treatment 
dose (35 versus 25 Gy, given in standard fractions of 1,8 Gy) [43]. Age at time of 
radiation predicts the decline in IQ following RT [32]. This is probably due to damage 
to the developing cerebral white matter by a mechanism not fully understood. Children 
treated with RT have reduced volumes of cerebral white matter on MRI as compared to 
non-RT treated age-matched controls [44].
EPENDYMAL TUMOURS 
Clinical symptoms, diagnosis and treatment
Ependymal tumours (ETs) can be found anywhere in the CNS. About one-third of ETs 
are located in the spinal canal [45]. About two-thirds of the intracranial ETs in children 
are located infratentorially and one-third supratentorially, while in adults it is inverse 
[9]. Two-thirds of the intracranial ETs occur in children, 96% of spinal ETs are seen in 
adults, with a peak incidence between 20-40 years of age [46].
Intracranial ependymal tumours
Clinical manifestations of ETs are site-dependent. The most common initial symptoms 
of posterior fossa tumours (nausea, vomiting and headache) are caused by increased 
intracranial pressure due to obstruction of CSF flow. Involvement of posterior fossa 
structures can cause ataxia, dizziness and paresis. Patients with supratentorial ETs 
may have focal neurological deficits, seizures, or features of increased intracranial 
pressure [47]. Clinical signs include papilloedema, meningeal signs, ataxia, cranial 
nerve palsy, and in children below the age of two years an increased head size or a 
bulging fontanel [9,47].
Radiological investigation is usually performed by MRI scanning, using both T1-
weighted images with and without contrast, and T2-weighted images. ETs demonstrate 
a hypointense signal on T1-weighted images. On T2-weighted images, they are 
hyperintense and generally well demarcated from surrounding brain. Inhomogeneous 
contrast enhancement occurs in most ETs [48]. CSF cytology and postoperative 
craniospinal MRI are needed for the stratification of patients into prognostic risk 
groups. Age of less than 3 years and posterior fossa localisation are associated with 
poor prognosis [49].
There are four ET histopatholoical subtypes. Low-grade ependymoma (lgE), the most 
common type of intracranial ET has two main characteristic histological features; 
anuclear perivascular collars of radiating cell processes (perivascular pseudorosettes) 
and true rosettes of tumour cells with a central lumen. LgEs are considered low grade 
(WHO grade II) [12]. Anaplastic or malignant ependymoma (aE) (WHO grade III) 
show higher cellularity, marked mitotic activity, and nuclear atypia with or without 
florid microvascular proliferation. Large areas of necrosis and high apoptotic rate 
are common findings [12]. Myxopapillary ependymomas (mpEs), (WHO grade I), 
are usually located in the conus-cauda region, and are characterised by cuboidal to 
elongated tumour cells radially arranged in a papillary manner around vascularised 
stromal cores [12]. Subependymomas (subE) are also considered low grade, and are 
classified as WHO grade I. They are characterised by clusters of isomorphic nuclei 
embedded in a dense fibrillary matrix of glial cell processes with frequent occurrence 
of microcysts. Mitosis are very rare or absent [12].
Molecular genetic findings of intracranial ETs are so far not incorporated into risk 
classifications. Most ETs show cytogenetic alterations. Abnormalities of chromosome 
22, mainly monosomy, are found in 30% of the tumours [50]. A large CGH study in 
paediatric ETs revealed that patients with a CGH pattern showing few, mainly partial 
imbalances, had a worse prognosis compared to the group showing 13 or more 
chromosome imbalances with a non-random pattern of whole chromosome gains and 
losses [51]. In this study, genetic imbalances and surgical resection predicted clinical 
outcome, whereas age, histopathology and other clinical parameters did not. The 
most common genetic abnormalities found in these studies were loss of chromosome 
22, gain of chromosome 1 and loss of chromosomes 6q and 17 [51-54]. Loss of 
chromosome 22, probably harbouring a tumour suppressor gene, is so far not related 
to outcome [52-54]. No underlying sequence of genetic events has been identified in 
the malignant progression from low to high-grade ETs so far.
Treatment of ETs starts with surgery aiming at radical resection. Radical resection is 
the most important factor for progression-free and overall survival [55-57]. The tumour 
residu is best estimated with post-operative MRI. Gross total resection is reported in 
50-73% of cases [55,56].
Post-operative RT has long been used for ETs, although randomised prospective 
studies are not available [49,55,56,57]. By consensus, a tumour dose of 54-55 Gy 
for lgEs and 60 Gy for aEs is given [57]. Craniospinal irradiation is applied to patients 
with leptomeningeal seeding [58]. To avoid neurocognitive and neuroendocriene 
complications, patients younger than 3 years old are usually treated postoperatively 
with a multi-agent ChT regimen instead of RT. The role of ChT is controversial. 
Robertson et al. concluded on the basis of a prospective trial (a regimen of 2 drugs 
versus 8 drugs) involving 32 children between the ages of 2 and 17 years, that 
9adjuvant ChT had no impact on progression-free survival [55]. Another study of 48 
children younger than 3 years of age treated with delayed RT and ChT suggested that 
ChT allows a delay in RT, and improve survival [59]. So far, ChT has no role in the 
adjuvant setting with the exception of children younger than 3 years [56,59].
Residual disease after surgery and CSF dissemination are the two most important 
clinical parameters affecting outcome [60]. In a study of 80 children, (aged 4 months to 
15.8 years, 38 with a complete tumour resection), relapses occurred from 3-72 months 
after diagnosis (median 25 months). Survival at 5-years for patients who had complete 
resection of the tumour is 75% vs. 41% for those with incomplete resection. For those 
who received RT, the 5-years survival was reported 65% vs. 23% for those who did 
not receive RT [61]. The value of MRI in follow-up has been established although it is 
not clear how frequent these should be performed. Patients with a surgical removal 
of an early, asymptomatic recurrence have a better prognosis as compared to those 
with a symptomatic recurrence [62,63]. The prognostic significance of histological 
malignancy grade in ETs is unclear. Some retrospective studies show that aEs carry 
a worse prognosis, but this was not confirmed in other studies [55,59,64].
Most recurrences are at the site of the primary tumour (59-78%) and complete 
resection is a key factor in long-term survival [61,62]. The role of RT and ChT in 
relapsing ETs is not well defined yet.
Spinal ependymomas
About one-third of ETs are localised in the spinal cord. Sixty percent of all spinal cord 
tumours in children and adults are ETs [45].
The interval between the onset of symptoms and diagnosis ranges from days to 
years. Pain is the most common initial symptom and is seen in about two-thirds of 
patients. Neurological signs are found in 70% of patients and include hyperreflexia, 
motor and sensory dysfunction, and spasticity. Sensory disturbances are the second 
most common symptom and are seen in 60% of cases. Fifty percent of patients have 
limb weakness, and one-third have bladder/bowel dysfunction [60].
MRI is the imaging modality of choice and usually reveals a sharply circumscribed 
lesion. T1-weighted images may demonstrate cysts associated with the tumour. 
Contrast enhancement allows for the differentiation between tumour and surrounding 
oedema [65].
The vast majority of spinal cord ETs are lgEs (WHO grade II) or mpEs (WHO grade 
I). LgEs are found throughout the spinal canal and can be situated both intra- and 
extramedullary. MpEs are usually located extramedullary in the conus-cauda region 
[46,66,67]. 
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A wide range of genomic alterations as detected by comparative genomic hybridisation 
is described in spinal lgEs and mpEs. Spinal lgEs relatively often show gain of 
chromosomes 2, 7, and 12 and loss of 14, and MpEs gain of chromosomes 9 and 18 
[52,68]. Allelic loss on 22q is frequently found in spinal lgEs [69]. Although mpEs are 
designated as a WHO grade I tumour and spinal lgEs as a WHO grade II, mpEs have 
on average more genomic alterations (as detected by CGH) and a higher percentage 
of aneuploidy than spinal lgEs [70].
Local control is the main factor influencing disease-free survival and can be obtained 
by radical surgery [71,72]. Complete resection, however, is only possible in 57-76% 
of the cases because of the risks of surgery-related neurological deficits [73,74]. RT 
after incomplete resection increases local control. The dose used is 45-50 Gy (in 
doses of 1,8-2 Gy) and the target volume consists only of the tumour bed with a 
suitable margin for clinical target volume and planning volume, as this tumour is not 
likely to relapse at distant sites [75,76]. In general, spinal lgEs and mpEs have a 
good prognosis. Late recurrences and distant metastases are rare [77,78]. Long-term 
neurological outcome is related to pre-operative conditions without clear differences 
between partially and totally resected tumours, and without impact of exact location. 
Seeding is seen in mpEs and reported more often these days, probably due to 
the use of MRI. It is interesting to report that these seeded tumours do not cause 
clinical symptoms in most of the patients, probably due to the small size and the low 
proliferation rate [75].
AIM OF THIS THESIS
MBs and ETs are among the most common primary CNS childhood tumours. 
Although new multimodality treatment regimens have substantially improved survival 
in this group, there is still a mortality rate of one-third for MB patients and 40% 
for intracranial ETs patients [26,63]. Further progress in the therapeutic approach 
requires translational research; the application of basic scientific discoveries into 
clinical findings and, simultaneously, the generation of scientific questions based on 
clinical observations. Combined molecular and histopathological analysis of tumours 
together with clinical staging will identify groups of patients with specific treatment 
requirements, avoiding overtreatment and improving mortality rate and event-free 
survival. Fortunately the progress in molecular biology and genetics has given us a 
much deeper insight into tumour induction and progression. Genomic, proteomic, and 
angiogenic studies have become important aspects of cancer research.
The studies presented in this thesis focus on identifying new molecular, morphological, 
and clinical features related to prognosis in MBs and ETs. For this purpose several 
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techniques were used. CGH was performed on MBs and ETs, and in an experimental 
glioblastoma xenograft study (chapters 2, 3, 4, and 6). To further substantiate the 
relation between genetic alterations and histopathological grading in ETs, DNA ploidy 
assessment was performed (chapter 4). We studied the expression pattern of insulin-
like growth factors (IGF)-I and -II mRNA, which may play an important role in tumour 
growth and development in MBs (chapter 5). Genetic alterations were correlated with 
prognostic factors and outcome. As angiogenesis, the outgrowth of new bloodvessels 
from the pre-existent vasculature, is a critical process for the local growth of tumours, 
we performed studies attempting to link the pattern of vascularisation with clinico-
biological behaviour. As glioblastomas are very well vascularised, an experimental 
study was done on the relationship between genetic alterations (as detected by 
CGH), growth rate, and vascularisation in glioblastoma xenografts (chapter 6). A new 
technique was used for the three-dimensional visualisation of the vascularisation 
pattern of MBs and ETs. The vascularisation pattern of the histopathological subtypes 
of MBs and ETs were analysed and compared with those of normal cerebral white 
and grey matter (chapter 7). Finally, a retrospective study on the use of RT for partially 
resected spinal ETs is presented in chapter 8.
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SUMMARY OF THE CYTOGENETIC TECHNIQUES USED
Comparative genomic hybridisation (CGH)
A molecular cytogenetic technique that screens chromosomal imbalances in tumours. 
CGH detects amplifications and deletions in a single experiment without the need 
for specific DNA probes or previous knowledge of chromosomal aberrations present. 
It provides an overview of chromosomal imbalances by comparing the hybridisation 
efficiency of tumour and reference DNA to normal metaphase chromosomes. Test and 
reference (tumour) DNA is differentially labelled (e.g. reference in red and test in green) 
with fluorochromes (direct labelling), or haptens (indirect labelling) which are later 
visualised by fluorescence. Both DNAs are mixed in a 1:1 ratio, and are in situ hybridised 
onto normal human metaphase chromosomes. During this co-hybridisation, tumour 
and reference DNA compete for the same targets on the metaphase chromosomes. 
The relative amount of tumour or reference DNA bound to a given chromosomal region 
is dependent on the relative abundance of these sequences in both DNA samples. 
Gains will show in green and losses will show in red, whereas regions that are normally 
present will show in yellow. The presence and localisation of these imbalances can be 
detected and quantitated by analysing the ratio test-fluorescence versus reference-
fluorescence (green/red) along the chromosome. Fixed thresholds of 1.2 for gain 
and 0.8 for loss were used [79]. The sensitivity depends on the percentage of cells 
containing the aberration, and the quality of the CGH experiment. The lowest amount 
of DNA copy number change reported is 10-12 Mb [80].
Fluorescence in situ hybridisation (FISH)
Intracellular labelling of single-stranded DNA or RNA with an immunofluorescent 
particle attached to a pairing DNA or RNA strand, in morphologically preserved 
biological structures such as chromosomes, cells and tissues.
DNA ploidy assessment
The measurement of DNA content. Ploidy refers to the number of copies of the 
chromosome in a cell. A normal cell has two copies of each chromosome (diploid). A 
haploid cell has one copy, a tetraploid cell has four copies, etc. DNA ploidy assessment 
can reveal genetic instability in a (sub)population of cells.
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ABSTRACT
Medulloblastomas are highly malignant primitive neuroectodermal tumours of the 
cerebellum that display a wide variety of histopathological patterns. However, these 
patterns do not provide an accurate prediction of clinical-biological behaviour and no 
satisfactory morphological grading system has ever been presented. Genetic alterations 
may provide additional diagnostic information and allow clinically relevant subgrouping 
of primitive neuroectodermal tumours. We examined ten medulloblastomas and one 
medulloblastoma cell line. One amplification site on chromosome 8q24 was detected 
in the cell line corresponding to the known amplification of the MYCC gene in this cell 
line. The gain of 2p21-24 in two tumours was shown to represent amplification of the 
MYCN gene by Southern blot hybridisation and fluorescence in situ hybridisation. 
The data show that the isochromosome 17 can be recognised using comparative 
genomic hybridisation (CGH) by the typical combination of loss of 17p combined with 
gain of 17q. No specific pattern of genetic alterations could be linked to the clinical 
behaviour of the tumours. We have compared our results with previous CGH studies 
on medulloblastomas.
INTRODUCTION
Medulloblastomas (MBs) are highly malignant primitive neuroectodermal tumours that 
probably arise from primitive neuroectodermal cells, constituting the external granule 
cell layer of the developing cerebellum. It is the most common paediatric brain tumour 
with an incidence of 5 cases per 1 million children each year [1]. The survival rate 
at 5 years is approximately 50% with a long-term survival rate of 30%, largely as a 
result of local re-growth and metastasis [2]. In addition, the survivors suffer from the 
adverse side effects of the treatment including mental retardation, stunted growth 
and leukoencephalopathy [3,4]. Designing new treatments aimed at achieving longer 
survival periods and fewer side effects will require individualised treatments based 
on prognostic factors. At present, only four such factors are available: age, extent of 
surgical resection, local spread to the brain stem, and the presence of metastases [5]. 
In contrast to gliomas, devising a grading system for MBs, which links pathological 
features to prognosis, has not been successful [6]. Genetic analysis of MBs could 
provide additional prognostic information because the biological behaviour of a 
tumour is ultimately determined by its genetic changes. For example amplifications 
of oncogenes MYCN, EGFR (Epidermal Growth Factor Receptor Gene) and MYCC 
appear to predict rapid progression of MBs [7-11]. In addition, the study of genetic 
alterations helps to understand the oncogenesis of MBs. Comparative genomic 
hybridisation (CGH) is the ideal technique for studying genetic changes in tumours, 
as it can detect amplifications and deletions in tumours without the need for specific 
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probes or previous knowledge of chromosomal aberrations present [6,12,13]. CGH 
provide an overview of all chromosomal imbalances by comparing the hybridisation 
efficiency of tumour and reference DNA to normal metaphase chromosomes [12]. 
The regions showing amplification or deletion by CGH can be further investigated 
using other genetic techniques such as fluorescence in situ hybridisation (FISH) and 
Southern blot assays. In this study, we used CGH followed by FISH and Southern 
blotting to identify genetic alterations in MBs and a MB cell line in order to detect 
genetic changes. We compared our results with other CGH studies on MBs to define 
the clinical significance of the detected chromosomal abnormalities.
MATERIALS AND METHODS
Patients and Tumours
The tumours for this study were obtained from the frozen brain tumour resource 
of Mayo Clinic. Ten fresh frozen tumours were selected from patients (3 female, 7 
male) ranging in age from 7 months to 33 years. The clinicopathological findings 
are summarised in Table 1. In all cases, the diagnosis of MB was confirmed by a 
neuropathologist (B.W.S.) using haematoxylin/eosin (H&E) stains. Five of the 10 MBs 
had desmoplastic features. A MB cell line (cell line 341) was obtained from the MB of 
a 3.5-year-old male during craniotomy [14].
Case Sex Age at operation Outcome Histology Metastasis
   (years)  (follow-up period)
1314 F 0.6 A, 7 yr Desmoplastic Mb none
968 F 33  A, 6 yr Desmoplastic Mb none
616 M 13 D, 3 yr Desmoplastic Mb local recurrence  
     and CSF
620 M 6 D, 5 yr Classic Mb local recurrence  
     and frontal bone
309 M 8  D, 2 yr Desmoplastic Mb  bone
622  M 12  A, 7 yr Classic Mb CSF
166 M 7  A, 9 yr Classic Mb None
167 M 10  A, 10 yr Classic Mb None
10 M 3  A, 7 yr Desmoplastic Mb  None
24 F 5  A, 7 yr Classic Mb None
cell line 341 M 3  D, 0.8 yr Classic Mb bone and  
     abdomen
Table 1 Clinical Data on the Patients. F: female; M: male; A: alive; D: dead; 
yr: year; classic MB: classic medulloblastoma; desmoplastic Mb: desmoplastic 
medulloblastoma; CSF: cerebral spinal fluid. 
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DNA samples and probe labelling
Reference genomic DNA from peripheral blood leukocytes of a healthy male donor 
was obtained and DNA was isolated from the tumour according to a standard protocol 
[15]. The probe was indirectly labelled by nick translation using the Vysis nick 
translation kit (Vysis, Downers Grove, IL). The tumour DNA was labelled with Biotin 
16-dUTP (Boehringer Mannheim, Indianapolis, IN) and the normal DNA was labelled 
with Digoxigenin 11-dUTP (Boehringer Mannheim).
CGH
Metaphase chromosomes were cultured from Phytohaemagglutinin-stimulated blood 
lymphocytes of a normal, healthy male donor according to standard cytogenetic 
procedures. Fixed metaphase suspensions were dropped onto slides in a controlled 
environment chamber (Thermatron Industries, Holland, MI). CGH was carried out 
as described elsewhere [16]. Briefly, slides with metaphase spreads were incubated 
with RNase A (Boehringer Mannheim;100mg/mL in 2 x SSC) for 1 hour (hr) at 37°C, 
digested with pepsin (Sigma, St. Louis, MO, 0.1 mg/mL in 0.01 M HCl) and post-fixed 
with formaldehyde (Fisher Scientific, Pittsburgh, PA; 1% in PBS with 50 mM MgCl2). 
The slides were denatured in 70% formamide/2 x SSC for 2 minutes (min) at 80°C. 
The probe mixture consisted of 223 ng of labelled tumour and normal DNA together 
with a 100-fold excess of Cot-1 DNA (Vysis) in 50% formamide, 2 x SSC, and 10% 
dextran sulfate. The probe solution was denatured for 5 min at 80°C, quenched on 
ice, and allowed to preanneal at 37°C for 1 hr. The probe was then applied to the 
denatured slide and hybridisation was carried out under a sealed coverslip for 72 hr in 
a moist container. Post hybridisation washes consisted of 3 x 5 min in 50% formamide/ 
2 x SSC at 37°C and 3 x 5 min in 0.1 x SSC at 60°C and once in 4 x SSC at room 
temperature. The slides were preincubated with 0.5% dry milk powder in 4 x SSC 
for 30 min at 37°C in a moist container. Avidin-fluorescein isothiocyanate (FITC, 
Boehringer Mannheim) was used to detect the tumour DNA and anti-digoxigenin 
rhodamine (Boehringer Mannheim) was used to detect the normal DNA (both diluted 
100-fold in 0.5% dry milk powder in 4 x SSC). The slides were incubated for 60 min at 
37°C in a moist container. Next, the slides were washed 3 x 5 min in 4 x SSC/0.05% 
Tween. Chromosome preparations were dehydrated and counterstained with 4’-6-
diamidino-2-phenylindoledihydrochloride (DAPI) for identification.
Image analysis
Images were captured with a Zeiss Axiophot fluorescence microscope (Carl Zeiss 
Inc., Thornwood, New York) equipped with a 100 Neo-Fluar objective, a computer 
controlled filter wheel, and a cooled CCD camera (Photometrics, Tucson, AZ) using 
Smartcapture IPLab Extensions software (Vysis). Image analysis was carried out on 
a PowerMac computer using Quips Imaging Software (Vysis). The fluorescence ratio 
(FR) of the FITC-to-rhodamine signals were averaged from 8 to 12 chromosomes 
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of each type. The average FR for the CGH experiments was 1.0 with a standard 
deviation of 0.05. Based on our previous experiments and the published requirements 
for quantitative analysis of CGH, FR thresholds of 0.80 and 1.20 were chosen to 
distinguish numerical and regional loss and gain, respectively [16-18].
Controls
All experiments were repeated once. Male control DNA was used in all experiments. 
Control procedures included CGH experiments using normal versus normal DNA and 
normal male versus normal female. CGH was also performed on DNA isolated from 
a tumour cell line (MPE 600) provided in the Vysis CGH Nick Translation kit (Vysis). 
This DNA was used as a positive control in each CGH experiment. All of the known 
abnormalities present in the Vysis tumour cell line were readily detected in each CGH 
experiment.
Southern blot analysis
Because the CGH experiment suggested that the oncogene MYCN may be amplified 
in some MBs, we assessed MYCN gene dosage by Southern blot on the tumour DNA. 
First the digested tumour DNA was transferred to a nylon membrane according to 
standard procedures. Hybridisation was carried out as described elsewhere [15]. 
 
After wetting the filter in 0.2 x SSC with 0.5% SDS, it was pre-hybridissed at 42°C 
in 50% formamide containing 6 x SSC, 5x Denhardt’s, 1% SDS, and 100 μg/mL 
denatured herring sperm DNA. The filter was then hybridised overnight at 42°C in a 
solution of the same composition, but containing 25 ng of plasmid pNB-1 (American 
Type Culture Collection, ATCC, Rockville, MD) labelled with 32P-dCTP to a specific 
activity of 5 x 108 cpm per μg by the random primer technique [19].
Following hybridisation, the filter was rinsed 2 x 5 min in 1xSSC with 0.1% SDS at 
room temperature, 1 x 5 min in 0.2 x SSC with 0.1% SDS at room temperature, 2 
x 30 min in 0.2 x SSC with 0.1% SDS at 60°C, and 2 x 5 min in 0.2 x SSC at room 
temperature before exposing it to X-ray film.
In order to control for MYCN signal variation associated with sample loading, the 
membrane was stripped of plasmid pNB-1 in 0.4 M NaOH and then rehybridised with 
the control probe KM.19. Autoradiograms associated with each hybridisation were 
scanned and resulting images were analysed for relative MYCN signal response 
using the NIH Image 1.52 software program.
Chromosome studies
Chromosome studies were performed on fresh material from 3 tumours and on the 
cell line using previously described methods [10].
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Fluorescence in situ hybridisation (FISH)
FISH was performed on paraffin-embedded tissue sections (5μm), which were 
mounted on glass slides. The slides were first deparaffinised (3 x 10 minutes in 
xylene), and dehydrated (2 x 5 min in 100% ethanol and 2 x 5 min in 95% ethanol). 
The slides were then treated with 0.2N HCl for 20 min at room temperature, washed in 
deionised water for 3 min and then in a phosphate buffered saline solution for 3 min. 
Next, the slides were placed in plastic coplin jars filled with 10mM citric acid (Sigma, 
pH 6.0) and microwaved on high-power for 10 min. The slides were removed from the 
jars, cooled to room temperature, and placed in 2 x SSC for 5 min. This was followed 
by tissue digestion in which 1 mL pepsin (Sigma, 4mg/mL) was placed on each slide 
and incubated at 37°C in a moist container for 15 min. The slides were washed in 
deionised water for 3 min and then placed in 2 x SSC for 5 min. Next, the slides were 
put into a coplin jar filled with 0.1M triethanolamine/acetic anhydride for 3 min at room 
temperature and then washed in 2 x SSC for 3 min. The hybridisation procedure has 
been described previously [6]. A biotin labelled alpha satellite chromosome 2 probe 
(Oncor, Gaithersburg, MD) and a SpectrumOrange labelled locus specific probe 
Figure 1 Summary of genetic imbalances detected by CGH in 10 MBs and one MB 
cell line. Lines on the left of each chromosome indicate losses, whereas lines on the 
right represent gains. Amplification sites are indicated by squares.
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for MYCN (Vysis) were the FISH probes used. Avidin-FITC was used for detection 
of the biotin probe. The signals were evaluated using a Zeiss Axioplan fluorescent 
microscope equipped for FITC, TRITC, and DAPI fluorescence.
RESULTS
CGH was performed using DNA from 10 primary fresh frozen tumours and 1 cell line. 
Figure 1 and Table 2 summarise the alterations detected by CGH for both the tumours 
and the cell line. The most frequently observed alteration involved chromosome 17. 
Gain of 17q was detected in 4 of the 10 primary tumours and in the cell line. In two 
cases (cell line 341 and case 622) gain of 17q was accompanied by a loss of 17p 
(Figure 2). The second most common aberration was the loss of chromosome 8, which 
was detected in 4 tumours. Also, 7q11.2 was gained in 2 tumours. Deletions of 13q 
were detected in 2 tumours; 1 of the whole arm and 1 of bands 13q21-qter. Deletions 
of 10q, 18q, and Y were each detected in 2 tumours. Gain of 1p and amplification of 
2p21-24 (MYCN region) were each detected in 2 tumours.
CGH results were compared with routine cytogenetic data, MYCN dosage analysis by 
Southern blot, and FISH studies. The results of these experiments are summarised 
in Table 2.
The Karyotypes were available for cases 1314, 968, and 622, and the cell line. For 
case 1314, the deletion detected on 10q was nonclonal, yet the CGH result showed 
loss in that region of chromosome 10 q-arm. The complex karyotype of case 968 shows 
several numerical and structural alterations, including deletion of 17p. However, CGH 
only detected loss of 14q and 18q. No abnormalities were found in the karyotype of 
case 622 although several gains and losses were detected by CGH. In addition, the 
amplification of 8q, loss of 17p, and gain of 17q detected by CGH in cell line 341 also 
matched the alterations detected in the karyotype.
The results of the Southern blot analyses showed a 5- and 1.9-fold amplification of 
MYCN in both tumours (616 and 166) with amplification of 2p21-24 (MYCN region) by 
CGH. FR thresholds were 1.5 and 2.0, respectively. Similarly, FISH analysis showed 
MYCN amplification for both cases.
No single abnormality could be linked to clinical-biological behaviour. A trend relating 
the number of genetic alterations to the survival rate was observed: both cases 616 
and 309 had short survival rates combined with a large number of genetic changes. 
Tumours with desmoplastic histology (1314, 968, 616, 309, 10) were not associated 
with specific genetic alterations.
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DISCUSSION
In this study, CGH was used to obtain an overview of genomic alterations in 10 MBs 
and 1 MB cell line. Nonrandom losses (2 or more cases) were found on chromosome 
regions 10q23-qter, 13q14-q22, 17p, and 18q22-qter and nonrandom gains (2 or more 
cases) were detected for regions 1p, 2p21-24, 7q11.2, and 17q. Nonrandom whole 
chromosome losses (2 or more cases) were detected for chromosomes 8 and Y.
Gain of the distal chromosome 2 p-arm was detected in 2 tumours (616 and 166). 
This region is of great interest in MBs because it contains the MYCN gene, which 
has been detected in about 7% of MBs and may be associated with a poor prognosis 
[8,9,20]. The MYCN amplification was increased 2-5-fold in both tumours. The cell 
line 341 showed amplification on the distal end of the chromosome 8 q-arm. This 
corresponds to the 20-fold amplification of MYCC previously established by Southern 
hybridisation (results not shown) [14]. Thus the gains of 2p and 8q in MBs as detected 
by CGH represent amplifications of MYCN and MYCC, respectively. These alterations 
constitute important steps in the oncogenesis of MBs, but their clinical relevance is 
as yet unclear [10,11].
Aberrations of chromosome 17 are frequently detected in MBs [20-32]. We found 
gains of 17q in combination with a loss of 17p in two cases (622, cell line 341, Figure 
2). The combination of 17q gain and 17p loss most likely represents the presence of 
Figure 2 CGH results for chromosome 17 indicating the presence of an iso 
chromosome 17(i[17q]). Average profiles are shown for cases 341 and 622 which 
both had a gain of 17q and a loss of 17p. The mode of the intensity ratios (middle 
line) and the thresholds for overrepresentation (right line) and underrepresentation 
(left line) are presented. FR thresholds of 0.80 and 1.20 were used to distinguish 
numerical and regional chromosomal loss and gain, respectively.
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isochromosome 17 (i[17q]) which is found in 30% of MBs [21,22,25]. This interpretation 
of the CGH pattern is supported by the presence of i[17q] in the karyotype of 
the cell line.
Several other anomalies were observed in this set of MBs by CGH. Tumour 616 
had amplification on 1p11-22, which has also been described in gliomas [33]. Two 
tumours showed a deletion of 10q22-10qter and potentially including the recently 
described ‘deleted in malignant brain tumour’ (DMBT) and ‘phosphatase and tensim 
homoloque delete on chromosome 10’ (PTEN) genes [34]. The deletion of 18q21-qter 
potentially includes the ‘deleted in colon carcinoma’ (DCC) gene [35]. Two tumours 
showed a deletion of 13q with a minimally deleted region of 13q14-22 which contains 
the retinoblastoma 1 (RB1), ‘disrupted in B cell malignancy 1’ (DBM1), and breast 
cancer 2 (BRCA2) genes [36].
So far, 150 primary MBs have been analysed by CGH [20,28-33]. An array of 
nonrandom genomic losses was found in most samples. Patterns of chromosomal 
gains and losses unique to MBs were not observed. Chromosomal imbalances most 
frequently involved chromosome 17 (loss of 17 p and gain of 17q) and losses of 
10q, 11 and 8. High-level amplifications were found on 2p24 and 8q24, suggesting 
involvement of MYCN and MYCC respectively [20,32] in concordance with our results. 
Three studies (62 patients) and one case report compared the clinical outcome of 
primary MBs with CGH results in the search for genetic alterations with potential 
prognostic value [27,29,31,32]. Nishizaki et al. suggested an association between 
the number of chromosomal changes and the unfavourable prognosis on the basis of 
only six cases [30]. The two larger studies (n = 56) and our results (n = 11) failed to 
identify specific genetic abnormalities or patterns associated with prognosis [27,31], 
although Nicholson et al. suggested an association of loss of chromosome 22 and a 
poor prognosis [31]. Much attention has been focused on aberrations of chromosome 
17, the most typical genomic alteration in MBs. Although an association between loss 
of heterozygosity (LOH) on 17p and adverse prognosis has been reported [7], these 
findings could not be reproduced in the CGH series comparing CGH with clinical 
outcome [27,29,31].
Prognosis has previously been linked to histological variant, with desmoplastic variants 
tending to have a more favourable outcome than classic MBs [37, 38]. We found 
no difference in survival between patients with desmoplastic and non-desmoplastic 
tumours. Nicholson et al. also failed to find a significant difference in prognosis 
between 14 patients with desmoplastic MBs and 17 patients with non-desmoplastic 
MBs [31]. However, our number of patients is too small to make any conclusions 
about this matter.
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Although CGH is a valid and reproducible technique for the detection of sub-
chromosomal gains and losses in solid tumours [13,16], the results are not completely 
concordant with cytogenetic analysis. Both our group and others [13,16] have 
observed this. The reasons for the discordant results are likely due to weaknesses 
of both procedures. Cytogenetic analysis only evaluates a limited number of clones 
present within each tumour. Routine cytogenetic analysis does not provide a complete 
overview of all genetic aberrations. Culturing solid tumours is difficult, and the cultures 
may be overgrown by normal cells. CGH only detects copy number changes involved. 
Translocations and inversions cannot be detected by CGH as they represent balanced 
alterations not involving loss or gain of DNA. Multiploidy cannot be detected by CGH, 
because equal amounts of tumour and control DNA are used in CGH experiments.
In conclusion, we were able to confirm that the gains of 2p and 8q represent 
amplifications of MYCN and MYCC respectively. CGH studies have failed to identify a 
single genetic aberration or pattern of alterations relating to biological behaviour.
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ABSTRACT
Ependymal tumours (ETs) are gliomas that arise from the ependymal lining of the 
cerebral ventricles and from the remnants of the central canal of the spinal cord. Both 
clinical and genetic studies suggest that distinct genetic subtypes of ETs exist, the 
subtypes being correlated with patient age and/or tumour site. In the present study 
the tumour genome of 20 ETs (15 adult and 5 paediatric cases) was screened for 
chromosomal imbalances by comparative genomic hybridisation (CGH). The most 
frequently detected imbalances were -22q (75%), -10q (65%), -21 (50%), -16p (50%), 
-1p (45%), +4q (45%), -10p (45%), -2q (40%), -6 (40%), -19 (40%), -2p (35%) -3p 
(35%), and -16q (35%). Comparison of the chromosomal imbalances detected in 
ETs to those previously reported in oligodendroglial and astrocytic tumours revealed 
that in this respect ETs show similarities to these other gliomas. By combining these 
results with those of a recent study of Zheng et al. and Hirose et al., it was found that, 
although ETs from different localisations and from adult and paediatric patients show 
overlap at the CGH level, some chromosomal imbalances occur predominantly in a 
certain category. In adult patients, spinal ETs relatively often showed +2, +7, +12, and 
-14q; infratentorial ETs -22; and supratentorial ETs -9. In addition, in posterior fossa 
ETs -6 and +9 were much more frequent in adults than in children. It is concluded 
that the genetic background of ETs is complex and partly determined by tumour site, 
histopathological subtype, and age of the patient.
INTRODUCTION
Ependymal tumours (ETs) are gliomas that are considered to arise from glial cells 
which normally cover the wall of the cerebral ventricles and of the central canal in 
the spinal cord. Although ETs are relatively common in childhood, they may occur at 
all ages [1,2]. According to the World Health Organisation (WHO) classification, ETs 
are subdivided into four categories: myxopapillary ependymoma (mpE, WHO grade 
I), subependymoma (subE, WHO grade I), low-grade ependymoma (lgE, WHO grade 
II), and anaplastic ependymoma (aE, WHO grade III). In addition, the most malignant 
glial tumour, i.e. glioblastoma multiforme (WHO grade IV), sometimes shows focal 
ependymal differentiation (GBM-E). Numerous studies have yielded conflicting results 
regarding the prognostic significance of histological parameters for patients with lgE or 
aE (for review see [3]). Clinical studies revealed that postoperative survival depends 
on age of onset, tumour site, and extent of tumour resection [1]. Furthermore, it is well 
established that tumour localisation and age of the patient are interrelated [1].
These clinical data suggest that distinct tumour entities exist among ETs, which may 
be age- or site-related. Indeed, age-related genetic pathways are suggested by loss 
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of heterozygosity (LOH) analysis, reporting LOH 22q to be a common finding in adult 
ETs that is only rarely present in a paediatric population [4]. Site-dependent genetic 
pathways are suggested by the observation that neurofibromatosis type-2 (NF-2) 
patients especially develop spinal ETs, and that sporadic spinal ETs are characterised 
by a high incidence of loss of 22q and NF-2 mutations [1,5]. 
In the present study we screened 20 glial tumours with ependymal differentiation for 
chromosomal imbalances throughout the entire tumour genome using comparative 
genomic hybridisation (CGH). We also analysed whether ETs show similarities to 
astrocytic and oligodendroglial tumours at the chromosomal level. Finally, the 
correlation between chromosomal aberrations, patient age, tumour localisation, and 
histopathological grading was analysed by combining our results with those recently 
reported by Zheng et al. in a group of 28 ETs [6], and with those of Hirose et al. in a 
group of 44 ETs [7].
MATERIALS AND METHODS
 
Surgical specimens of 15 adult and 5 paediatric tumours selected for the present 
study were obtained from patients treated at the University Medical Centre Nijmegen 
and the St. Elizabeth Hospital Tilburg, The Netherlands. During surgery, part of the 
tumour was snap-frozen in liquid nitrogen and stored at -80°C. 
Hematoxylin and eosin-stained (H&E) paraffin sections of each tumour were classified 
according to the WHO 2000 classification [1] as mpE (n=2), lgE (n=12), or aE (n=4). 
For grading an ET as aE, the tumour had to show at least three of the following four 
histopathological features: high cellularity, marked nuclear polymorphism, brisk mitotic 
activity (10 or more per mm2), and florid microvascular proliferation. In addition, two 
cases of glioblastoma multiforme with local ependymal differentiation in the form of 
perivascular pseudorosette formation were included in this study (GBM-Es). Apart 
from these ependymal features (that are illustrated in Figure 1), these two GBM-Es 
histopathologically showed astrocytic differentiation, necrosis, and all four features for 
high-grade malignancy as mentioned above.
CGH was performed essentially as previously described [8], with minor modifications. 
Tumour and normal DNA were differentially labelled using biotin-dUTP or digoxigenin-
dUTP (Roche Molecular Biochemicals, The Netherlands) in nicktranslation and the 
probe was prepared as described [8]. The probe and metaphase spreads were 
denaturated simultaneously using the OmniSlide Thermal Cycler (5 minutes 37°C, 
3 minutes 72°C followed by approximately 60 hours at 37°C) (Thermo-Hybaid, 
Middlesex, UK). Detection and analysis was performed as described [8] using 
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streptavidin-FITC and sheep-anti-digoxigenin-TRITC (Roche Molecular Biochemicals, 
The Netherlands) and the QUIPS CGH software (Applied Imaging, UK). The standard 
thresholds for gains (1.2) and losses (0.8) were used, aberrations of 1.4 and 0.6 
were called clear copy number changes and aberrations (1.6 were called high copy 
number gains). The quality of our CGH experiments was monitored by including both 
a negative and positive control experiment [8].
Combining the CGH results of Zheng et al. (28 ETs) [6] and Hirose et al. (44 ETs) [7], 
with those in our group of 20 ETs, the correlation between chromosomal imbalances, 
patient age, tumour site, and histopathological grading was analysed. An overview 
was created of the frequency of gains and losses on each chromosome arm for 
different tumour localisations in adult and paediatric ETs. 
RESULTS
Clinical data and histopathological diagnosis of the 20 analysed tumours are shown in 
Table 1. Histopathological analysis identified 2 mpEs, 12 lgEs, 4 aEs, and 2 GBM-Es 
(Table 1). In the group of adult tumours (n=15), 8 occurred in the spinal canal (53%) 
whereas the other 7 were intracranial tumours (47%) (3 in the posterior fossa and 4 
supratentorial). In contrast, all paediatric tumours (n=5) were intracranially located 
(3 posterior fossa and 2 supratentorial). The CGH results are summarised in Table 1 
and depicted in Figure 2. The mean number of aberrations per tumor was 11 (range 2 
to 25). Frequently detected chromosomal imbalances (present in 7 tumours or more) 
were -22 (15/20), -10q (13/20), -16p (10/20), -21 (10/20), -1p (9/20), -10p (9/20), +4q 
Figure 1 Ependymal features in glioblastomas. Illustration of perivascular 
pseudorosette formation that was only focally present in two high-grade malignant 
glial tumours (N91, N213), included in the present study as glioblastomas with focal 
ependymal differentiation (GBM-Es).
N91 N91
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(9/20), -2q (8/20), -6p (8/20), -6q (8/20), -19 (8/20), -2p(7/20) -3p (7/20), and -16q 
(7/20). The common regions of overlap of these regions are -10q25-qter, -1p31-pter, 
+4q11-32, -2q33-qter, -6q23-qter, 2p16-24, and -3p14-24. 
In Figure 3, an overview is shown of the frequency of gains and losses involving 
the individual chromosome arms for spinal, posterior fossa, and supratentorial ETs 
in adults, and for paediatric posterior fossa and supratentorial ETs. In this figure we 
combined our CGH results with those previously reported by Zheng et al. [6] and 
Hirose et al [7]. The mpEs and GBM-Es were not included in this overview.
 
DISCUSSION
Chromosomal imbalances detected by CGH in ETs
A loss of 22 was the most frequently detected aberration in our group of ETs (75%). 
Other chromosomal imbalances frequently detected were: -10q (65%), -21 (50%), 
-16p (50%), -1p (45%), +4q (45%), -10p (45%), -2q (40%), -6 (40%), -19 (40%), -2p 
(35%) -3p (35%), and -16q (35%). In general, our results are in concordance with 
those of Zheng et al. [6], whereas the frequencies reported by Hirose et al. [7] are 
Figure 2 Summary of all chromosomal imbalances as detected by CGH in adult and 
paediatric ETs. Lines on the left and right of the chromosome indicate losses and 
gains of these chromosomal regions respectively. A thin line indicates aberrations 
crossing the 0.8 or 1.2 threshold, a heavy line indicates a clear copy number change 
(crossing the ratios 0.6 and 1.4), and an additional spot on the bar indicates a high 
copy gain. Aberrations in adult ETs are indicated by a continuous line, aberrations in 
paediatric ETs by a discontinuous line.
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Figure 3. An overview of the frequency of chromosomal imbalances in ependymal 
tumours at different sites, based on combination of the results of the present study 
and those of Zheng et al [6] and Hirose et al. [7]. A positive percentage represents the 
frequency of a gain, whereas a negative percentage represents the frequency of a loss. 
The chromosome arms are indicated at the bottom of the figure. Maximum differences 
between different tumour localisations in adults exceeding 35% are indicated by *, 
whereas such differences in paediatric tumours are indicated by +. Differences 
between adult and paediatric ETs at the same site (posterior fossa or supratentorial) 
are indicated by #. Used abbreviations: n = number of analysed tumours.
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lower. In several LOH studies, LOH 22q in ETs ranged from 0% to 100% [5,9-11]. 
Differences between individual studies on ETs are also present for the involvement of 
NF-2 in ETs [5]. These discrepancies may reflect site- or age-related genetic pathways 
that lead to the formation of distinct subsets of ETs [5,12]. The common region of 
overlap of frequently detected aberrations most likely contains genes involved in 
the oncogenesis of ETs. Since Zheng et al. [6] and Knuutila et al. [13,14] already 
elaborated on this subject, we will not discuss this topic further. 
Recently, two other CGH studies on ETs were published [2,15]. The results of these 
studies are not included in our overview of the authors’ CGH findings in ETs. In one 
of these papers, a difference exists in the sensitivity of their CGH experiment using 
either the “standard” or “reverse” labelling technique (as shown by their Figure 2), 
which may result in an underestimation of the number of aberrations [2]. In the other 
paper, some chromosomal regions were excluded from analysis [15], as early CGH 
papers reported that false positive results may occur at 1p32-pter, 16, 19, and 22 
[16]. However, after refining CGH, such artefacts are only occasionally detected [17] 
and partially depend on the quality of the metaphase chromosomes and of the two 
labelled DNAs [18]. Interestingly, in contrast to 1p32 pter, 16, and 19 which were 
excluded from analysis, chromosome 22 was analysed in their study and -22 and +22 
was reported to be present in less than 10% and 23% of the 26 ETs, respectively [15]. 
A +22 was only detected in 2% and -22 in 53% of the 92 ETs analysed by Zheng et al. 
[6], Hirose et al. [7], and our group.
Comparison of ETs and other gliomas
Although one study reported resemblance at the molecular genetic level between ETs 
and astrocytic and oligodendroglial tumours (As and OTs) [9], others reported that 
aberrations involved in the oncogenesis of ATs were rarely detected in ETs [1,4,5,19]. 
OTs very frequently show loss of 1p and 19q [8,20-23]. Losses involving these 
regions were detected in 8 (40%) of the ETs analysed by us, but often a complete 
loss of chromosome 19 and a partial loss of 1p were detected. We did not find a 
correlation between aberrations of chromosome 1 or 19 in ETs and the presence of 
oligodendroglial features in these tumours at the histopathological level.
 
Genes involved in the two main cell-cycle regulatory pathways at the G1-S border, 
the RB1 pathway and the P53 pathway, are reported to be involved in ATs [24-28]. 
For the RB1 pathway it was shown that a loss of CDKN2A (9p21), amplifications of 
CDK4 (12q13.3-q14), and inactivation of RB1 (13q14.3) are alternatives for escape of 
growth control [24-27]. For the P53-pathway, TP53 (17p13) mutations or deletion, and 
amplification of mdm2 (12q13) appear to be alternatives for escape of growth control 
[28]. Our current results show that 13 of the 20 ETs harbour aberrations including 
+12q13 (CDK4), -9p21 (CDKN2A), and/or -13q14 (RB1), suggesting that the RB1 
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pathway is involved in the oncogenesis of a proportion of the ETs. Furthermore, 12 
of the 20 ETs showed aberrations including -17p13 (TP53) and/or +12q13 (mdm2), 
indicating that the P53 pathway may also be involved in the oncogenesis of these 
tumours. No correlation was detected between the involvement of these pathways 
and age, tumour site, or histopathological diagnosis. 
Histopathological classification
Two of the ETs included in the present study were diagnosed as GBM with focal 
ependymal differentiation in the form of perivascular pseudorosettes (N213 and N91) 
(Figure 1). A CGH study of 100 GBMs reported as most frequent aberrations
-10q (77%), -10p (59%), +7 (75%), and -9p (59%) [29]. N213 contained none of 
these aberrations, whereas N91 contained +7, and -9p. These latter aberrations are 
also detected in lgEs. While -22 is the most frequently detected aberration in ETs, 
this aberration was not detected in the two GBM-Es. However, both GBM-Es are 
supratentorial localised and -22 was detected in only 33% of the supratentorial ETs 
in adults analysed by us, Zheng et al. [6], and Hirose et al. [7] (discussed below). 
Additionally, losses smaller than 10-12 MB are undetectable by CGH and might still be 
present on 22 [30]. It remains to be seen if such GBM-Es should indeed be separated 
from ordinary GBMs and included in the group of ETs as a grade IV tumour.
According to the WHO classification, mpEs are a distinct entity within the group of 
ETs. They are slow growing, grade I tumours with a generally favourable prognosis 
[1]. Since chromosomal imbalances accumulate during (malignant) progression of 
tumours, it was unexpected to find such an extensive array of genomic aberrations 
(13 in N273, 19 in N270). Both mpEs included in the present study showed clear 
similarities with regard to the chromosomal aberrations; -1pter-p31, +4p14-qter, 
+5p13-q31, -10, -14q, -16p, -19, and -22 were detected in both tumours, implicating 
that these chromosome arms probably contain genes that are important for the 
oncogenesis of mpEs in adults. As these aberrations were occasionally detected in 
the previously analysed paediatric mpEs [7], it remains to be established whether 
different genetic pathways exist for adult and paediatric mpEs. 
LgEs may show malignant progression to aEs [1]. Although -22 was detected in 12 
of the 13 lgEs, only 2 of the 4 aEs contained this aberration. Furthermore, although 
tumours generally show accumulation of genetic aberrations during malignant 
progression, the aEs contained fewer aberrations than the lgEs (an average of 5 in 
aEs, and 13 in lgEs), suggesting that different genetic pathways exist for lgEs and 
aEs. However, since all aEs were intracranially located, whereas approximately half 
of the lgEs occurred in the spinal canal, such differences between lgEs and aEs at the 
CGH level may also reflect site-dependent pathways.
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Age- and site-related differences
As adult patients fare better than paediatric patients and LOH 22q was reported to be 
a common finding in adult (but not in paediatric) ETs, age-related genetic differences 
might exist [1,4]. Furthermore, the observations that patient age and tumour site are 
interrelated [1], that patients with neurofibromatosis type 2 (NF-2) disease develop 
spinal ETs, and that sporadic spinal ETs often show an altered NF-2 gene and LOH 
22q [5,11], suggest a correlation between molecular genetic aberrations and tumour 
site. To identify age- or tumour site-dependent genetic pathways in ETs, we combined 
our results with those reported in the CGH study of Zheng et al. [6] and Hirose et al. 
[7]. Since overall only 3 paediatric spinal ETs were analysed, these tumours were not 
included. Additionally, as mpEs may be a distinct entity and it is not clear whether 
GBM-Es should be regarded as ETs, only the lgEs and aEs were analysed for this 
purpose.
The differences in the distribution of chromosomal imbalances for ETs in the 
supratentorial compartment, spinal canal and posterior fossa are illustrated in Figure 
3. In ETs of adult patients, the following site-related differences in chromosomal 
imbalances as detected by CGH exceeded 35%: +2 in 38% of the spinal ETs; -2p in 40% 
of the posterior fossa ETs which never gained this chromosome; +7 in approximately 
in 60% of the spinal ETs, in 30% of the posterior fossa ETs, and occasionally in 
supratentorial ETs; -9 in 50% of the supratentorial ETs; +12 in approximately half of 
the spinal ETs, in one-third of the posterior fossa ETs, and occasionally in spinal ETs; 
-14q in 39% of the spinal ETs and -22 in 81% of the spinal ETs. Similarly, differences in 
distribution of chromosomal imbalances for intracranial paediatric ETs were detected: 
+1q and -6q are detected in 50% of the supratentorial and in 6% of the posterior fossa 
ETs. Overall these results suggest site-dependent genetic pathways for both adult 
and paediatric ETs.
Differences between adult and paediatric ETs of the same site were also noticed; 
-6 and +9 are detected in 53% of the adult posterior fossa ETs and in only 6% or 
less of the paediatric ETs at this localisation and -9q is detected in 50% of the adult 
supratentorial ETs and in 13% of the paediatric supratentorial ETs. Thus, this analysis 
offers evidence for the existence of genetic pathways for ETs that are not only site-
dependent, but also age dependent. 
In conclusion, our CGH study shows that the oncogenesis of ETs is rather complex and 
that -22 and -10q are the most frequently detected aberrations in these tumours. As in 
other gliomas, the RB1 and the P53 pathway seem to be involved in the oncogenesis 
of a proportion of the ETs. Since GBM-Es show some differences with ordinary GBMs 
at the CGH level, it remains to be seen if these tumours should be regarded as grade 
IV ETs rather than as ordinary GBMs. Combining our results with those of Zheng et 
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al. [6] and Hirose et al. [7], we have shown that different chromosomal imbalances are 
involved in the oncogenesis of ETs in adults that are correlated with tumour site; -22 
was most frequently detected in infratentorial ETs, -9 was most frequently detected in 
the supratentorial ETs, whereas +2, +7, +12, and -14q were most frequently detected 
in spinal ETs. Furthermore, differences between posterior fossa or supratentorial ETs 
in children and adults suggest that age-related chromosomal imbalances exist. For 
further elucidation of the genetic background of Es, more tumours should be analysed 
with a large enough number in each subgroup as determined by patient age, tumour-
site, and histopathological subtype.
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ABSTRACT
The goal of our study was to investigate the inverse correlation between number 
of genetic aberrations and malignancy grade in ependymal tumours (ETs) at the 
ploidy level. We examined 7 myxopapillary ependymomas (mpEs) (WHO grade I), 28 
spinal and cerebral low-grade ependymomas (lgEs) (WHO grade II) and 18 cerebral 
anaplastic ependymomas (aEs) (WHO grade III) using image DNA cytometry. The 
ploidy status was correlated with clinicopathological characteristics and with the 
results obtained by comparative genomic hybridisation (CGH) analysis that we 
performed in about half of these tumours. MpEs were exclusively located in the spinal 
cord and aES in the cerebrum only, whereas lgEs were located in both the spinal 
cord and brain. We found aneuploidy or tetraploidy to be common in the group of 
mpEs (6 out of 7) and much less frequent in lgEs (6 out of 28) and aEs (4 out of 18). 
Three-year postoperative survival was 100% for mpEs, 100% for spinal low-grade 
Es, 92% for cerebral lgEs and 33% for aEs. Our CGH results in a selection of these 
tumours revealed the highest number of genetic aberrations in the mpEs (average 
16; n=2), a lower number in lgEs (average 12; n=11) and the lowest number in aEs 
(average 5; n=6). Interestingly, in the group of low-grade Es and aEs, a high number 
of genetic aberrations as detected by CGH was not correlated with aneuploidy or 
tetraploidy. Three patients, all with mpEs, had local seeding. These results underline 
that mpEs are distinctly different from lgEs and aEs at the genetic level and that 
extensive genomic alterations and aneuploidy in ETs are not in itself an indicator of 
malignant behaviour.
INTRODUCTION
Ependymal tumours (ETs) are considered to originate from ependymal cells of 
the wall of the cerebral ventricles, the central canal of the spinal cord, and from 
ependymal remnants in the filum terminale. They constitute 3-9% of all neuroepithelial 
tumours, and 50-60% of spinal gliomas [1]. The World Health Organisation (WHO) 
classification of central nervous system tumours recognises various types of ETs; 
low-grade ependymomas (lgEs; WHO grade II), anaplastic ependymomas (aEs; 
WHO grade III), and myxopapillary ependymomas (mpEs; WHO grade I). MpEs occur 
predominantly in the conus-cauda region and are histopathologically characterised 
by tumour cells arranged in a papillary manner around vascularised stromal cores, 
with low or absent mitotic activity. Although mpEs generally do not progress to 
higher malignancy grades, they can disseminate in the subarachnoidal space [1,2]. 
Apart from perivascular pseudo-rosettes and true rosettes, lgEs are microscopically 
characterised by moderate cellularity, monomorphic nuclear morphology, and low 
or no mitotic activity. In contrast, aEs typically show high cellularity, brisk mitotic 
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activity, nuclear atypia, and in part of the cases florid microvascular proliferation and 
pseudopallisading necrosis.
Malignant progression of tumours is generally associated with accumulation of 
genetic aberrations in tumour cells [3]. Recently, several studies on ETs described 
a correlation between genomic alterations and tumour grade, localisation, patient 
age, and prognosis [4-7]. Surprisingly, some of these studies, including our own, 
revealed that lgEs carried on average more genomic alterations than aEs, while in 
mpEs the number of aberrations exceeded that in lgEs and aEs [5,6,8]. In order to 
further substantiate (and unravel) this inverse correlation, we performed Image DNA 
cytometry on a series of mpEs, lgEs, and aEs, and compared the results of the ploidy 
measurements with the clinico-pathological characteristics, as well as with the CGH 
results that we previously obtained in part of these tumours [6]. 
PATIENTS AND METHODS
Patients and tumours
Fifty-three ETs (42 primary, 10 recurrences, 1 metastasis) from 49 patients (25 males, 
24 females, aged 1- 69 years) who were operated on between 1985 and 2000, 
were derived from the University Medical Centre St Radboud Nijmegen and the St 
Elisabeth Hospital Tilburg, The Netherlands. Table 1 summarises the age and sex of 
the patients, and the location, ploidy status and histological findings of the tumours. All 
lgEs and aEs were intraparenchymal, cerebral or spinal tumours, all mpEs intradural 
tumours were located in the lumbosacral region. The histopathological diagnosis was 
made on hematoxylin and eosin (H&E) stained histological sections according to the 
WHO 2000 criteria [1]. Follow-up data were available for at least three years after 
operation.
DNA ploidy assessment
Ploidy assessment was performed on all tumours using a Discovery Fluorbance 
system (software verrsion 2.61sp, Beckton Dickinson Cellular Imaging Systems, 
Leiden, The Netherlands). The cytospin specimens were scanned fully automatically 
with a 25 x objective (NA = 0.7) using a motorised stage and automatic focussing. 
Microscopic fields measuring 550 x 550 μm were digitised by a Xillix MicroImager 1400 
monochromatic CCD camera (Xillix Technologies Corp, Vancouver, British Columbia, 
pixel size 6.8 x 6.8μm2, 8 bit sampling), resulting in an effective resolving power of 
0.54 x 0.54 μm2. Images were digitised at λ = 580 nm for detection of nuclear Feulgen 
staining. At this wavelength the staining showed maximum absorbance. Detection of 
nuclei was performed in 3 steps:
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1. By automated adjustment of the lamp voltage and by use of a shading correction 
algorithm the intensity of image points (pixels) belonging to the background (i.e. 
no staining is present) was kept at grey value of 200. Next, all pixels in the image 
with grey value below a threshold value were considered to be Feulgen-positive. 
This threshold value was set at 4 times the standard deviation of the background 
peak (calculated from a smooth histogram) below this peak.
2. Neighbouring (8-connected) image pixels that were positive for Feulgen were 
grouped together to form objects that possibly correspond to nuclei. Holes inside 
objects were filled.
3. For each object the area and the contour ratio were determined. Contour ratio 
is defined as 1000 x perimeter / ( 2 x √ ( π x area ) ), describing the roughness 
of the contour of an object. Artefacts were removed by applying thresholds to 
these parameters. Parameter threshold values were determined for use in the 
entire study from manually selected, correctly recognised objects from a number 
of specimens. Objects with area over 150 pixels and contour ratio smaller than 
1200 were used [9].
Objects found in this way were considered to represent correctly recognised, single 
(i.e. non-overlapping) nuclei. For all nuclei the integrated optical density (IOD) was 
calculated as a measure for the total amount of DNA. If 800 nuclei were detected 
before the entire specimen area was scanned, the measurement procedure was 
stopped.
Images of measured nuclei were displayed on the computer screen in a gallery 
display. For each specimen approximately 20 nuclei of reference cells and 200 nuclei 
of ET cells were manually selected. The IOD histogram of reference cells was visually 
inspected and a reference value was determined such that the reference cell peak 
in the calibrated IOD (cIOD) histogram had a value of 0.89. This number is found 
experimentally, to correct for the effects of diffraction and glare on small, dense 
objects on the IOD. Although others advise an upper-bound of 5% [10], in our study 
(probably due to the pre-processing of the specimens) this limit was too vigorous and 
cases with coefficient of variation (CV) of the reference cells smaller than 15% were 
accepted. Next, the cIOD histogram of each specimen was manually classified as 
either diploid or deviating from diploid by three observers. Consensus was reached 
for every case.
Comparative genomic hybridisation
Comparative genomic hybridisation (CGH) was performed on snap frozen tissue as 
previously described [6]. For logistical reasons, snap frozen tissue was only available 
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of 19 tumours. Briefly, normal DNA and tumour DNA were labelled with digoxigenin-
dUTP (Boehringer Mannheim) and biotin-dUTP (Boehringer Mannheim) in a standard 
nick translation system, respectively. The pre-treated metaphase slides and the 
probes were denaturated simultaneously and hybridisation was performed for three 
days. After hybridisation, the slides were washed stringently and the biotinylated DNA 
was detected using streptavidin-FITC and the digoxigenin-labelled DNA with sheep-
anti-digoxigenin-TRITC. Chromosomes were counter-stained with 4’-6-diamidino-2-
phenylindole (DAPI) to identify the chromosome-banding pattern. A relative gain was 
scored when the mean tumour-reference ratio was > 1.2 and relative loss was scored 
when the ratio was < 0.8. Aberrations of 1.4 and 0.6 were called clear copy number 
gains or losses respectively. Aberrations > 1.6 were called high copy number gains. 
Adequate controls were included in all experiments as described by Jeuken et al. [6].
RESULTS
Survival
Survival data and patient characteristics are summarised in Table 1 and Figure 1. 
All patients with spinal ETs were alive after three years or died of unrelated causes. 
Eighty-six percent of patients with cerebral lgEs survived 3 years, against only one-
third of patients with cerebral aEs.
 
Ploidy assessment
Ploidy assessment results are summarised in Table 1 and Figure 1. Of the 7 mpEs, 
only one was diploid. The rest was aneuploid (n = 4), or tetraploid (n = 2). One of the 
14 spinal lgEs was aneuploid, 3 were tetraploid, and the rest (n = 11) were diploid. 
Figure 1 Percentage of diploidy, aneuploidy, and tetraploidy.
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Two of the 13 cerebral lgEs (15%) and 3 of the 18 cerebral aEs (16%) were aneuploid. 
Three patients, all with mpEs, had local seeding in the spinal canal. Two of these 
disseminating tumours were aneuploid. The number of patients who died due to their 
ET was too small to determine the influence of ploidy status on survival.
CGH
CGH results are shown in Table 2 and Figure 2. A wide range of genomic alterations 
was detected, the most frequently being loss of chromosome 22 (n = 14), loss of 17 (n 
= 5) and gain of 4q (n = 8). CGH showed less genomic alterations in the aEs (average 
5) compared to the lgEs (average 12), while the mpEs showed the highest number 
of genomic alterations (average 16). No specific genomic alteration was correlated to 
histological grade or ploidy status.
DISCUSSION
In several tumour types the ploidy status was shown to carry prognostic information. 
For example, in cancer of bladder, prostate and ovary, aneuploidy correlates with a 
poor prognosis [11]. In colorectal tumours aneuploidy is associated with malignant 
progression [12]. On the other hand, diploid and near triploid neuroblastomas show 
poor and excellent clinical outcomes, respectively [13]. So far, in the limited number 
of DNA ploidy studies on ETs no correlation was found between tumour behaviour 
and ploidy status. However, most of the tumours examined were cerebral lgEs and 
aEs [14,15].
Our study shows a high percentage of mpEs with aneuploidy. This is in line with the 
findings of the interphase cytogenetics study of Scheil et al, in which an aneuploid 
karyotype was found in about half of the mpEs [8]. The percentage of spinal and 
cerebral lgEs/aEs with aneuploidy was much lower. 
As others and we described previously, a wide range of genomic alterations was 
detected in ETs by CGH [4-8]. Interestingly, these studies showed that aEs had 
on average the lowest and mpEs the highest number of genetic aberrations [4-
6,8]. Although there was no absolute relationship between the number of genomic 
alterations by CGH and ploidy assessment in our patients and the groups are small, 
the different groups differed clearly in this matter. AEs and cerebral lgEs were mostly 
diploid and aEs had fewer genomic alterations than the cerebral lgEs. Spinal lgEs 
showed less genomic alterations on average than mpEs, which were more often non-
diploid than lgEs. A similar relationship between cytogenetic aberrations by CGH and 
ploidy status is found in other tumours [12,16,17].
56
C
as
e 
 
S
ex
/ 
H
is
to
lo
g
y/
 
C
G
H
 lo
ss
es
 
C
G
H
 g
ai
n
s 
P
lo
id
y
 
 
A
g
e 
Tu
m
o
u
r 
si
te
 
 
 
as
se
ss
m
en
t
 N
27
0 
30
/m
 
M
pE
 /s
pi
na
l 
1p
te
r-
p3
1,
 1
q,
 2
p1
6-
24
, 2
q3
3-
qt
er
, 3
p1
4-
24
, 
4p
14
-q
te
r, 
5p
14
-q
31
, 9
pt
er
-q
31
, 
A
ne
up
lo
id
 
 
 
6q
23
-q
te
r, 
6p
, 1
0,
 1
1,
 1
4q
, 1
6p
, 1
7,
 1
9,
 2
2 
12
p1
2-
q2
1,
 1
8
N
27
3 
32
/f 
M
pE
 /s
pi
na
l 
1p
te
r-
p3
1,
 4
pt
er
-p
15
, 8
p,
 1
0,
 1
2p
, 1
3q
, 1
4q
, 1
6p
, 
4p
14
-q
te
r, 
5p
13
-q
31
, 7
q2
1-
 
Te
tra
pl
oi
d
 
 
  
19
, 2
2 
 
31
N
22
2 
56
/m
 
lg
E
 /s
pi
na
l 
16
, 2
2 
12
 
Te
tra
pl
oi
d
N
22
1 
48
/m
 
lg
E
 /s
pi
na
l 
21
C
, 2
2C
 
7,
 1
2 
A
ne
up
lo
id
N
22
6 
56
/f 
lg
E
 /s
pi
na
l 
1,
 2
, 3
, 6
, 8
, 1
0,
 1
1,
 1
3q
, 1
4q
, 1
6,
 1
9,
 2
0,
 2
1,
 2
2 
4,
 5
, 7
, 9
, 1
8 
D
ip
lo
id
N
22
9 
39
/m
 
lg
E
 /s
pi
na
l 
2q
, 6
q,
 1
3q
, 2
2 
19
 
Te
tra
pl
oi
d
N
23
1 
45
/f 
lg
E
 /s
pi
na
l 
1p
, 4
p,
 5
, 6
p,
 9
, 1
0,
 1
9,
 2
0q
, 2
1,
 2
2 
2,
 3
, 4
q,
 8
q1
1-
23
, 1
3q
, 1
4q
 
D
ip
lo
id
N
22
5 
32
/f 
lg
E
 /s
pi
na
l 
2,
 3
, 6
, 1
0,
 1
6,
 1
7,
 2
1,
 2
2 
4,
 9
, 1
3q
, 1
4q
 
D
ip
lo
id
N
26
9 
25
/m
 
lg
E
 /c
er
eb
ra
l 
1p
te
r-
p2
2,
 2
p,
 2
q3
2-
qt
er
, 6
, 8
p,
 8
q2
3-
qt
er
, 1
0,
 
4q
, 9
 
D
ip
lo
id
 
 
  
 1
6q
, 2
1,
 2
2,
 x
 
 
N
27
1 
48
/f 
lg
E
 /c
er
eb
ra
l 
1p
te
r-
p3
1,
 1
0q
23
-q
te
r, 
14
q,
 1
6p
, 1
9,
 2
0,
 2
1,
 2
2 
4q
 
D
ip
lo
id
N
26
7 
24
/f 
lg
E
 /c
er
eb
ra
l 
1p
11
-3
1,
 2
, 3
, 4
, 6
, 7
, 9
, 1
0,
 1
1,
 1
2,
 1
3q
, 1
8,
 2
1 
1q
, 5
, 8
, 1
9,
 X
 
D
ip
lo
id
N
26
6 
10
/f 
lg
E
 /c
er
eb
ra
l 
1,
 2
, 3
, 6
, 8
, 1
0,
 1
2,
 1
3q
, 1
4q
, 1
6,
 1
7,
 2
1,
 2
2 
7,
 9
q,
 1
1C
, 1
5q
, 1
8C
, 2
0 
D
ip
lo
id
N
22
8 
17
/f 
lg
E
 /c
er
eb
ra
l 
2,
 3
, 6
p,
 1
0,
 1
1p
te
r-
q1
3,
 1
6,
 1
7,
 1
9,
 2
0q
, 2
1,
 2
2 
4 
D
ip
lo
id
N
87
 
4/
m
 
A
E
 /c
er
eb
ra
l 
- 
2p
te
r-
p2
2*
, 1
1q
14
-2
2C
 
D
ip
lo
id
N
22
7 
2/
m
 
A
E
 /c
er
eb
ra
l 
10
q,
 1
6p
, 2
2 
X
 
D
ip
lo
id
N
22
4 
1/
m
 
A
E
 /c
er
eb
ra
l 
17
, 1
9,
 2
0q
, 2
2 
X
 
D
ip
lo
id
N
91
 
60
/m
 
A
E
**
 /c
er
eb
ra
l 
6q
, 9
p2
1-
pt
er
, 1
2p
, 1
4q
, 1
5q
11
-2
2 
7,
 1
2q
13
-1
5*
 
D
ip
lo
id
N
21
3 
34
/f 
A
E
**
 /c
er
eb
ra
l 
21
 
12
q,
 1
2q
11
-2
1C
, 1
3q
22
-q
te
r 
Te
tra
pl
oi
d
N
76
 
25
/m
 
A
E
 /c
er
eb
ra
l 
3p
te
r-
q2
4,
 5
q,
 1
0q
, 1
1,
 1
3q
, 1
8,
 2
1 
9q
 
A
ne
up
lo
id
Ta
b
le
 2
 C
G
H
 fi
nd
in
gs
 o
f 1
9 
E
Ts
. f
: f
em
al
e;
 m
: m
al
e;
 c
: c
le
ar
 c
op
y 
nu
m
be
r; 
*:
 h
ig
h 
co
py
 n
um
be
r, 
ra
tio
 >
 1
.6
, *
*:
 in
cl
ud
ed
 fe
at
ur
es
 
of
 g
lio
bl
as
to
m
a 
m
ul
tif
or
m
e.
57
MpEs are grouped together with lgEs and aEs in the category of ETs. The designation 
of respectively WHO grade I, II, and III to these tumours suggests tumours with different 
malignancy grades within the same spectrum. However, the typical histopathology 
and radiology [18] already indicate that mpEs form a separate entity. On the basis 
of their CGH results, Hirose et al. suggested that mpEs and spinal lgEs are different 
genetic sub-groups [5]. Also within the group of lgEs and aEs, different subgroups on 
the basis of localisation (spinal, posterior fossa, supratentorial) and age (paediatric 
versus adult population) have distinct genetic characteristics [5,6,19]. The results of 
our ploidy and CGH study support the idea that mpEs belong to an entity that is 
distinct from lgEs and aEs. Furthermore, it is entirely possible that in some diploid 
tumours relatively subtle aberrations strongly enhance malignant behaviour, while 
other tumours are aneuploid and harbour widespread genetic aberrations that do not 
lead to malignant behaviour. The result of this is that low-grade tumours can have 
more widespread genomic abnormalities as shown by CGH than high-grade tumours 
and can show a higher percentage of aneuploidy. Thus, this inverse correlation in ETs 
between the number of genetic aberrations and malignancy grade is caused by the 
following reasons. First, mpEs are not a precursor of higher-grade ETs but a separate 
entity. Second, genomic alterations are not necessarily an indication of malignant 
behaviour. Most patients with diploid aEs died, whereas the patients with the non-
diploid mpEs were alive and well. Other examples of the latter are neuroblastomas 
with aneuploidy, which have a better prognosis than their diploid counterparts with 
fewer genetic aberrations [20].
Dissemination of mpEs usually occurs only within the subarachnoidal space and is 
probably due to their extramedullairy/ intradural location rather than to aggressive 
tumour behaviour. Seeding within the intradural space is distinctly different from 
metastases at distance, and thereby not a sign of aggressive tumour behaviour.
Figure 2 Number of genetic alterations by CGH.
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In conclusion, our results confirm that mpEs are genetically distinctly different from 
lgEs and aEs. Furthermore, it supports the idea that genomic imbalances and 
aneuploidy are not necessarily an indicator of malignant behaviour of a tumour, 
despite its potential for dissemination. 
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ABSTRACT 
Insulin-like growth factors (IGFs) play an important role in tumour growth and 
development. We hypothesised that this is also the case for medulloblastomas, 
which are highly malignant cerebellar brain tumours usually occurring in children. In 
these tumours the expression patterns of IGF-I and II mRNA were studied. Tumour 
specimens obtained from 12 children and 2 adults at diagnosis were hybridised in 
situ with digoxigenin-labelled cRNA probes for hIGF-I and hIGF-II mRNAs. In all 
cases, tumour cells showed abundant expression of IGF-I mRNA. Nine of the 14 
tumours showed variable but significant IGF-II expression. In these tumours, the 
hybridisation signal almost exclusively co-localised with a sub-population of Ki-M1P 
positive cells that were identified as ramified microglia (RM) cells. In the 5 tumours 
without IGF-II expression, microglia/brain macrophages with a more rounded 
amoeboid-like morphology predominated. RM cells in normal cerebellar tissues, 
residing abundantly in areas of the white and, to a lesser extent, in the grey matter, 
were IGF-II mRNA-negative. These RM cells showed a thinner and more extensively 
branched appearance and were more evenly distributed than those encountered 
in medulloblastoma. Probably, during the transformation from the resting ramified 
towards the amoeboid morphology (or vice versa) IGF-II mRNA expression is only 
temporarily induced. The physiological meaning of the induction of IGF-II mRNA 
expression by these cells in medulloblastoma remains unclear but any IGF-II peptide 
synthesised could exert unfavourable mitogenic and anti-apoptotic effects on adjacent 
tumour cells. However, in this relatively small number of cases we could not find any 
indications for a relationship between clinical characteristics of the various cases and 
the extent of IGF-II mRNA expression.
INTRODUCTION
Medulloblastomas (MBs) are primitive neuroectodermal tumours of the cerebellum. 
They represent the most common malignant paediatric central nervous system (CNS) 
tumours and account for approximately 20-25% of all malignant intra-cranial neoplasms 
in childhood [1]. MB is believed to originate from the undifferentiated external granule 
layer in the cerebellum, but the mechanism of tumorigenesis remains unknown [2,3]. 
Several reports suggest that the insulin-like growth factor (IGF) system contributes to 
the development of MB [4-8].
IGFs are small polypeptide mitogens that resemble pro-insulin in structure. Through 
binding to the IGF-I receptor, they elicit metabolic, growth promoting and anti-apoptotic 
effects in many types of cells, including oligodendroglia [4,9]. IGF-I is considered 
to mediate many of the growth promoting actions of growth hormone, whereas the 
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closely related IGF-II merely acts as an autocrine growth and motility factor during 
prenatal growth and development [10,11]. Evidence is accumulating that IGFs 
function as autocrine growth factors in a variety of tumours, including those of the 
CNS, where they are involved in the control of proliferation of previously transformed 
cells [4,9]. The IGF signal transduction system may even play a role in the process of 
transformation itself [4,9].
Del Valle et al. [8] showed that the majority of MBs examined by them (i.e. 16 of 20 
cases) abundantly expressed the IGF-I receptor. In addition, the presence of the IGF-
I receptor protein and IGF-I mRNA has been demonstrated in cell lines of human MB 
[6]. However, data on IGF-I mRNA expression in MB tissue are scarce.
At present, little is known about IGF-II mRNA expression in MB. Loss of imprinting 
of the maternal allele of the IGF-II gene, leading to biallelic expression, can occur in 
human MBs (and MB cell lines), although this does not necessarily lead to enhanced 
mRNA levels [12]. Since biallelic expression of IGF-II is also observed in foetal 
cerebellum, its occurrence in MB presumably merely reflects the tumour’s embryonic 
nature.
In the present study we investigated both IGF-I and IGF-II mRNA expression in surgical 
resection specimens from 14 cases of MB by in situ hybridisation. This technique was 
used in order to address the question which cell types actually express IGF-I and 
IGF-II mRNA. Both normal human and porcine cerebellum samples were included 
as controls.
MATERIALS AND METHODS
Tissue specimens of patients and controls
Surgical resection specimens from 14 histologically proven and classified [1] cases 
of MB (all located in the posterior fossa) were investigated. Patient and tumour 
characteristics are summarised in Tables 1 and 2, respectively. Tissue samples of 
normal cerebellar tissues from subjects without neurological signs and symptoms 
(2 males, aged 1 and 48 years) were obtained at 5.5 hr post-mortem and used as 
controls. The Netherlands Brain Bank (Amsterdam, the Netherlands) provided these 
tissues. In all cases the rules of the Medical Ethical Committees have been observed. 
Because it was not possible to obtain normal human cerebellar tissue without post-
mortem delay and the porcine IGF-system resembles that of humans in many aspects 
[13], we also included cerebellar tissues from healthy new-born piglets (n=5) as 
controls [14]. All tissue samples were directly fixed in PBS-buffered formalin 3.8% 
(v/v) for 24 hours. After dehydration in a series of ethanol and incubation in xylol, the 
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tissues were embedded in paraffin. Sections (8-10 μm) were cut and mounted onto 
glass slides pre-treated with 3-aminopropyltriethoxysilane (TESPA) (Sigma-Aldrich, 
St.Louis, MO, USA), and stored at 4ºC until analysis by in situ hybridisation (8-10-μm 
sections) and immunohistochemistry (4-μm sections).
In situ hybridisation
Digoxigenin(DIG)-labelled cRNA probes were prepared by standard RNA synthesis 
reactions with T7- or T3-RNA polymerase using DIG-UTP (Roche Molecular 
Biochemicals, Mannheim, Germany) as substrate [15]. Complementary DNAs 
encoding a part of hIGF-I (nucleotides 120-379) [16], hIGF-II (containing exons 7, 8, 
and part of 9 of the human IGF-II gene) [17], and human ribosomal 28 S RNA [18], 
were used as templates for the synthesis of anti-sense and sense DIG-labelled cRNA 
probes. The 28S ribosomal DIG-cRNA probes were used to evaluate the preservation 
of RNA in the various tissue specimens studied. In situ hybridisation was performed 
overnight at either 51°C (IGF-I mRNA), 63°C (IGF-II mRNA) or 55°C (28 S ribosomal 
RNA), following procedures described previously [19]. The DIG-labelled RNA-
RNA hybrids were detected by sheep-anti-DIG Fab-fragments coupled to alkaline 
phosphatase and subsequent chromogenesis with nitroblue tetrazolium and 5-bromo-
4-chloro-3-indolyl-phosphatase [19]. This method yields a blue precipitate. Sections 
were counter-stained with nuclear fast red, dehydrated through a series of ethanol 
and mounted with Euparal (Waldeck GmbH and Co. KG, Münster, Germany).
Patient  Histological Leptomeningeal IGF-II mRNA
number subtype seeding in situ hybridisation
1 Classic yes -
2 Classic yes +
3 Desmoplastic no +
4 Classic yes +
5 Classic yes -
6 Desmoplastic no -
7 Large cell yes +
 Classic1 no +
9 Desmoplastic no -
10 Classic no +
11 Classic no -
12 Classic1 yes +
13 Classic1 yes +
14 Desmoplastic No +
Table 2 Characteristics of the MBs. 1 with local desmoplastic features.
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Immunohistochemistry
Immunohistochemistry was performed using Ki-M1P as a primary antibody 
(kindly provided by Dr. M.R. Parwaresch; University of Kiel, Kiel, Germany). This 
mouse monoclonal antibody reliably recognises a formalin/ paraffin-resistant 
differentiation epitope (CD68) of microglia and brain macrophages [20,21]. Prior to 
immunohistochemistry, paraffin sections of tumours and normal cerebellum tissues 
were mounted on Superfrost microscope slides (Menzel-Glaser, Braunschweig, 
Germany), dewaxed, and re-hydrated. For antigen retrieval, sections were placed 
in a 0.05 M sodium citrate buffer (pH 6.0) in a microwave oven with a rotating 
plateau (Miele Supratronic M752) and heated for 30 min at 700 W. After heating 
the slides were allowed to cool in the retrieval solution for at least 20 min before 
further processing. Subsequently, the sections were treated with 0.3% H2O2 to block 
endogenous peroxidase activity and incubated with Ki-M1P monoclonal antibody 
(diluted 1:5000 in PBS, containing 1% bovine serum albumin) for 1 h. Sections were 
stained by using the PowerVision+ TM poly-HRP-anti-mouse immunoglobulin kit, 
according to the protocol supplied by the manufacturer (ImmunoVision Technologies, 
Co., Brisbane, CA, USA). Copper sulphate-enhanced 3,3-diaminobenzidine (Sigma-
Aldrich, St. Louis, MO, USA) was used as a chromogenic substrate. All incubations 
were performed in a dark moist chamber at room temperature. Sections were counter-
stained with Mayers’ haematoxylin (Merck, Darmstadt, Germany) and mounted with 
Quick-D mounting medium (Klinipath, Duiven, the Netherlands).
Histological examinations
The various sections were examined by light microscopy using a Zeiss Axioscope 
microscope and photographed by a digital AxioCam HRc camera and AxioVision 
Reference 3.0 software for image processing (Carl Zeiss, Oberkochen, Germany). 
The abundance of IGF-I and IGF-II mRNA, and Ki-M1P immunoreactivity in each 
tissue section, as encountered by in situ hybridisation and immunohistochemistry, 
respectively, was judged to be negative (-) or positive (+) on blinded microscope 
slides by three independent investigators.
RESULTS
In situ hybridisation
All MBs, control human cerebellar tissues, and brain tissues obtained from 
new born piglets included in this study showed abundant presence of human 
ribosomal 28 S RNA (data not shown), pointing to the integrity of the RNA in 
the various tissue sections investigated. Subsequently, IGF-I and IGF-II mRNA 
expression patterns in the various MBs and control tissues were analysed by 
in situ hybridisation using anti-sense DIG-labelled hIGF-I and hIGF-II cRNA 
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probes, respectively. In all cases, sections hybridised with the corresponding 
sense probes were virtually negative.
Figure 1 Histochemical analysis of paraffin-embedded sections of a MB tumour 
specimen (i.e. tumour number 6) being representative for those tumours that do not 
show significant IGF-II mRNA expression. Sections were either hybridised with an 
anti-sense (A) or a sense digoxigenin-labelled (DIG) IGF-I cRNA probe (B). Purple 
or blue staining indicates the presence of IGF-I mRNA. C: in situ hybridisation with 
an anti-sense DIG cRNA specific for human IGF-II mRNA. D: immunohistochemistry 
was performed on successive paraffin tissue sections using a monoclonal antibody 
Ki-M1P. This antibody is considered to predominantly recognise cells belonging to 
the microglia / brain macrophage lineage (brown staining), in this case predominantly 
IGF-II mRNA negative more rounded amoeboid-shaped cells. Counter-staining was 
performed with haematoxylin. Original magnification for all panels, x 200.
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In all the 14 MBs investigated, small rounded tumour cells abundantly expressed IGF-
I mRNA. Representative examples are shown in Figure 1, 2, and 3. IGF-I mRNA 
could also be detected in endothelial cells of blood vessels. The presence of IGF-I 
mRNA in microvessels, however, was difficult to assess, due to diffuse and strong 
staining of the tumour sections. In normal human (Figure 3) and porcine cerebellar 
tissue, only Purkinje cells were IGF-I mRNA positive. Nine of the 14 tumour specimens 
investigated showed variable but specific expression of the IGF-II gene. However, IGF-
II mRNA could not be detected in tumour cells. The hybridisation signal appeared to 
be associated with dispersed cells exhibiting elongated nuclei, scanty cytoplasm, and 
fine polar or ramified processes (Figure 2 and 3). An exception was case 7, a ‘large cell’ 
MB [22], where IGF-II mRNA was also detected in relatively large cells with rounded 
morphology. It may be that the latter type of cells in fact represented tumour cells but 
this could not be established with certainty. In general, the IGF-II mRNA expressing 
microglia-like ramified cells showed a rather diffuse distribution pattern within the 
tumours (Figure 2) but tended to reach a higher density in perivascular spaces. In 
several cases of desmoplastic MBs and classic MBs with local desmoplastic features 
(i.e. tumours 3, 8, 13, and 14) containing reticulin-free nodules or ‘pale islands’ [23], 
IGF-II mRNA expressing ramified cells were abundantly present around, but not within 
these “pale islands” (Table 2 and Figure 2). In the sections of the two control human 
cerebellar tissues only the meninges were weakly positive for IGF-II mRNA (Figure 3). 
The same result was obtained for cerebellums from piglets (data not shown).
Immunohistochemistry
Because the morphology of the IGF-II mRNA positive cells in the various MBs resembled 
that of ramified microglia (RM) cells, this was verified immunohistochemically using 
Ki-M1P antibody that specifically recognises the microglia/ brain macrophage cell 
lineage. Careful, comprehensive comparison with successive sections stained for Ki-
M1P revealed that in all relevant cases the IGF-II mRNA hybridisation signal strongly 
co-localised with Ki-M1P positive ramified cells (Figures 2 and 3). In fact, all tumour 
specimens showed pronounced staining with the Ki-M1P monoclonal antibody. 
Besides RM cells, also more rounded amoeboid-shaped cells were found to be Ki-
M1P- positive. In most cases amoeboid-shaped cells predominated, except in cases 
3 and 8. In tumours 1, 5, 6, and 11, showing virtually no IGF-II mRNA expression, 
RM cells contributed less than 20% of the total population of Ki-M1P positive cells 
(Figure 1). Both cell types were scattered among neoplastic cells and also present 
(especially RM cells) around capillaries, larger blood vessels and ‘pale islands’. 
Usually, a few Ki-M1P positive amoeboid-shaped cells were found within ‘pale islands’ 
(Figure 2). Examination of the normal human cerebellum tissue revealed that Ki-M1P 
immunopositive RM cells by far predominated and resided abundantly in areas of the 
cerebellar white and, to a lesser extent, in the cerebellar grey matter (Figure 3). It was 
also noted that in general RM cells in the normal cerebellar tissues showed a thinner 
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Figure 2 Sections obtained from tumour specimen 8 (panels A-C). A: in situ 
hybridisation for mRNA expression of IGF-I; B: diffuse distribution pattern of IGF-
II mRNA expressing ramified microglia (RM) cells being representative for various 
other MB tumours. C: immunohistochemical reactivity of monoclonal antibody Ki-
M1P. IGF-II mRNA hybridisation signal strongly co-localised with Ki-M1P positive RM 
cells. Representative example (case number 3; panels D-F) of IGF-I mRNA (D) and 
IGF-II mRNA (E) expression in MB specimens containing areas with reticulin-free 
nodules (‘pale islands’), being comprised of cells with round ‘neurocytic’ nuclei and 
abundant cytoplasm. IGF-II mRNA expressing RM react immunohistochemically with 
monoclonal antibody Ki-M1P (F), whereas the few Ki-M1P positive amoeboid-shaped 
cells within ‘pale islands’ were IGF-II mRNA negative. Original magnification for all 
panels: x 200.
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and more extensively branched appearance and were more evenly distributed than 
those encountered in MBs. Similar results for Ki-M1P immunohistochemistry were 
obtained for cerebellums of healthy piglets (data not shown).
DISCUSSION
IGFs are thought to play a pivotal role in the proliferation of MBs [9]. Several lines of 
evidence (mainly based on studies on the IGF-receptor and components involved in 
signal transduction) suggest that this occurs in an autocrine fashion. Patti et al. [6] 
reported that an autocrine loop involving the IGF-I receptor activates proliferation of a 
human MB cell line. Tumour cells in MB may exhibit relatively enhanced protein levels 
of the IGF-I receptor (when compared to e.g. cells of the granular layer and Purkinje 
cells in normal human cerebellum) and its major signal transducing substrate, insulin 
Figure 3 Expression of IGF-I mRNA (A) and IGF-II mRNA (B) in Purkinje cells and 
meninges, respectively, of normal human cerebellum. C and D: a representative 
example of Ki-M1P positive RM cells in white matter of normal human cerebellum. 
Original magnification for panels A, B, and C: x 200; D: x 400.
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related substrate-1 [7,8]. In addition, phosphorylated (i.e. activated) forms of several 
downstream signalling proteins such as Erk-1, Erk-2, and Akt/protein kinase B have 
been detected in MBs, but not in control cerebellar tissue [8].
In the present study we demonstrate that a large proportion of the small neoplastic 
cells in MB highly express IGF-I mRNA. This finding complements the results of the 
studies referred to above.
Several reports indicate that (at least in rodents), following brain injury, activated 
microglia also express the neuroprotective IGF-I [24]. Moreover, IGF-I may stimulate 
the proliferation of microglia [25]. Because of the extensive DIG staining of the various 
MB sections investigated by us (due to the abundant presence of tumour cells), we 
could not reliably identify individual Ki-M1P immunoreactive cells that were also IGF-I 
mRNA positive. In normal human cerebellar tissue IGF-I mRNA could only be detected 
in Purkinje cells, in agreement with previous reports on this subject [26].
IGF-II is considered to play an important role in the foetal development of the brain where 
it is abundantly expressed. Beyond the perinatal period, IGF-II expression in the human 
cerebellum has been shown to persist primarily in the meninges, the mRNA  being 
transcribed from both parental alleles [27,28]. Our in situ hybridisation experiments 
on normal brain tissue of piglets and humans confirmed that IGF-II mRNA expression 
was indeed restricted to this region. Nine out of the 14 MBs analysed were found to be 
positive not only for IGF-I but for IGF-II mRNA as well. Surprisingly, and in contrast to 
the situation for IGF-I, in all cases (with the possible exception of the anaplastic/ large 
cell MB) neoplastic cells did not contain any histochemically detectable IGF-II mRNA. 
Instead, IGF-II mRNA expression appeared to be specifically associated with ramified 
Ki-M1P positive (i.e. CD68 antigen bearing) microglia. Albrecht et al. investigated the 
phenomenon of loss of imprinting (LOI) of the IGF-II gene in both MB cell lines and 
MBs [12]. LOI had occurred in one of four informative cell lines, although the particular 
cell line (MEB-MED-5) was derived from a tumour that originally exhibited imprinting 
of the IGF-II gene. The LOI of IGF-II in this cell line was not associated with increased 
expression of IGF-II mRNA, since two rounds of RT-PCR were required to generate 
enough cDNA-PCR product from the cell line. Three out of 7 informative tumours also 
showed LOI but again one could not establish a correlation between the presence 
and absence of imprinting of the IGF-II gene and IGF-II mRNA levels. Similar results 
were obtained by Zahn et al. for Ewing’s sarcoma [29]. Using immunohistochemistry, 
Ogino et al. could not detect any IGF-II protein in the 5 MBs investigated by them [30]. 
The reason for this apparent discrepancy remains unresolved, although in their paper, 
Ogino et al. did not provide data on morphological features of the MBs investigated. It 
cannot be excluded that they have studied tumours, which predominantly contain the 
more rounded, IGF-II mRNA negative, microglia.
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Cultured rat microglia (both resting and activated) have been shown to produce IGF-II 
that prevents (TNF)-alpha (derived from the same microglia) induced apoptotic death 
of oligodendrites in vitro [29]. The synthesis of IGF-II peptide by infiltrated microglia-
like cells is also induced during wound repair, following hypoxic-ischemic injury in the 
developing rat brain [30]. In addition, IGF-II mRNA and peptide are also induced in 
macrophage-like cells after global ischaemia in adult rats [32]. Similarly, a high number 
of infiltrating microglia/ brain macrophages is found in most human brain tumours. A 
study by Roggendorf et al. [21] indicates that the distribution pattern of these Ki-
M1P positive cells is distinct in various CNS neoplasms, underscoring the complex 
immunological function of the microglia/ macrophage cell system that expresses a 
wide variety of growth factors and cytokines. Indeed, in all MBs investigated by us 
these cells appeared to be abundantly present and exhibited, to a varying degree, 
either a ramified or a more rounded, amoeboid-like morphology. It is likely that the 
former type of cells represents microglia cells in a certain degree of a resting state. 
The exact function of these resting microglia is largely unknown but they may play 
a role in the surveillance, protection, and survival of neurons and oligodendrocytes 
[31-33]. RM cells were also found in the medulla and molecular layer of normal 
cerebellar tissues. However, in general their appearance seemed to be more slender 
and extensively ramified and virtually lacked IGF-II mRNA expression. Therefore, it 
cannot be excluded that these cells play another role when compared to the IGF-II 
mRNA positive cells encountered in the various tumour tissues. It is known that resting 
microglia respond to disturbances in their microenvironment by surrounding damaged 
neurons or other cells [33,34]. The outward sign of such activation is retraction of 
their branches leading to a more rounded amoeboid morphology. Depending on the 
severity of the tumour-induced injury, activated cells may either ultimately become 
phagocytic functioning as macrophages or transform back to a resting state [31,32]. 
Probably, during the transformation from the resting ramified towards the amoeboid 
morphology (or vice versa) IGF-II mRNA expression is only temporarily induced. The 
physiological meaning of the induction of IGF-II mRNA expression by these cells 
in MB remains unclear but one may speculate that any IGF-II peptide synthesised 
could exert unfavourable mitogenic and anti-apoptotic effects on adjacent tumour 
cells. However, although only a relatively low number of cases were investigated, we 
could not find any indications for a relationship between clinical characteristics of the 
various cases and the extent of IGF-II mRNA expression.
In summary, the results of the present study support the view that IGF-I is involved 
in the development and growth of MB and that the IGF system represents a potential 
target for future therapeutic approaches. Further studies should verify the expression 
of IGF-II by infiltrating microglia at the protein level and whether these cells express 
other growth factors and/or cytokines simultaneously.
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ABSTRACT
Angiogenesis is of vital importance for the growth of solid tumours and constitutes a 
target for anti-cancer therapy. Glioblastomas (GBMs) are histologically characterised 
by striking microvascular proliferation. The identification of the mechanism of 
angiogenesis is of major importance for the further development of anti-angiogenic 
therapy. Tumour angiogenesis might be the result of a combination of local tissue 
conditions (especially hypoxia) and specific genetic alterations acquired during 
oncogenesis. In order to investigate the relationship between genetic aberrations and 
tumour angiogenesis in GBM xenografts lines, the genetic alterations were examined 
by comparative genomic hybridisation (CGH). Two vascular phenotypes of GBM 
xenografts could be identified: a well vascularised and a poorly vascularised type. In 
this model, the poorly vascularised type had a greater number of genetic alterations. 
However, there was no unequivocal correlation between angiogenesis, growth rate 
and genetic alterations as detected by CGH.
INTRODUCTION
Angiogenesis is a critical process for the local growth of solid tumours and for metastasis 
[1,2]. Glioblastoma multiforme (GBM), the most frequent and most malignant of 
primary brain tumours, is characterised by aggressive intracerebral growth and the 
absence of metastases [3]. Hence, the prognosis of patients with GBMs is determined 
by local growth. At present no effective therapies are available [4,5]. GBMs are 
characterised by florid angiogenesis, which constitutes a target for new anti-cancer 
therapies [2,6,7]. Discovering the mechanisms involved in angiogenesis is essential 
for the development of therapeutic strategies aimed at neovascularisation.
Angiogenesis is regulated by angiogenic peptides, which appear to be produced in 
reaction to local hypoxia [8,9]. This is illustrated by the fact that Vascular Endothelial 
Growth Factor (VEGF), one of the main regulators of endothelial proliferation, is over-
expressed in cells adjacent to hypoxic tissue [9,10]. Alternatively, tumour angiogenesis 
might be influenced by amplification of genes coding for factors that promote 
angiogenesis or loss of genes coding for endogenous inhibitors [11-13]. Thus, tumour 
angiogenesis might be facilitated and sustained by clonal expansion of tumour cells 
with specific genetic aberrations [12,13]. This is supported by the finding of induction 
of capillary-like tube formation in cultured endothelial cells by glioma cells in the 
absence of hypoxia [14,15]. Since GBMs acquire structural chromosomal alterations 
not present in less malignant diffuse astrocytic neoplasms, a direct relationship 
between genetic alterations and angiogenesis can be postulated [16]. GBMs show, 
in contrast to low-grade and anaplastic astrocytomas, both prominent glomeruloid 
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microvascular proliferation and classic angiogenesis [17]. The striking heterogeneity 
of the microvasculature in GBMs might be related to genetic heterogeneity within a 
GBM [17].
The aim of this study is to examine whether patterns of angiogenesis are related 
to genetic alterations as detected with comparave genomic hybridisation (CGH) in 
10 GBM xenograft lines. With respect to tumour vascularisation, these lines have 
shown stable line-specific characteristics with striking differences between the lines, 
covering a range of well to poorly vascularised tumours [18]. In the present study, 
we quantitatively analysed the patterns of vascularisation and perfusion of the 10 
xenografts lines as described by Bernsen et al. [18]. The parameters measure the 
process of neoplastic vascularisation. In our opinion, this is the best quantitaitve 
measure of angiogenesis as it represents the functional end-result of the many factors 
and procesesses involved in angiogenesis. CGH is the ideal technique for studying 
genetic changes in tumours, as it can detect losses and gains in tumours without the 
need for specific probes or previous knowledge of chromosomal aberrations present 
[19]. In this study the relationship of these patterns in comparison to angiogenesis is 
investigated by CGH. 
MATERIALS AND METHODS
Patients and xenografts
Xenografts were derived from supratentorial GBMs of 10 patients (4 female, 6 male, 
age 33-70 years) (Table 1). A neuropathologist (PW) diagnosed the original tumours 
according to the criteria of the World Health Organisation [4]. The pathologic specimens 
were obtained by subtotal resection and 7 representative samples were used for 
implantation [18]. Tumours were passaged subcutaneously in nude mice (BALB/c 
nu/nu mouse) as described by Bernsen et al. [19]. Tumour volume was calculated by 
the formula: Volume = length x width x height x π/6 [19]. Growth rate was measured 
weekly by an experienced observer and expressed as mm3/week. Growth rate was 
arbitrarily divided in fast (more than 30 mm3/week), moderate (between 10 and 30 
mm3/week) and slow (less than 10 mm3/per week). Tumours were harvested before 
reaching a volume of 1 cm3. The growth rate and vascularisation fro all xenografts 
were stable during passaging and line-specific [18].
Quantification of angiogenesis and hypoxia
Athymic mice bearing a subcutaneous human GBM in the right flank were injected 
intravenously with 2 mg of the hypoxic marker pimonidazole-hydrochloride in PBS 
and with 15 mg kg-1 of the perfusion marker Hoechst 33342 (Sigma, St Louis, MO, 
USA) in PBS 30 minutes and a few minutes before the animals were sacrificed, 
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respectively [18,20,21]. Tumours were snap-frozen and stored in liquid nitrogen. From 
each sample, a total of four frozen sections were taken, containing both central and 
peripheral regions. The sections were air dried and fixed in acetone for 3 min after 
which they were washed 10 min in PBS. To visualise the vasculature, sections were 
first incubated with the monoclonal rat anti-mouse endothelium antibody ME 9F1 [22] 
after fixation for 10 minutes in acetone. The sections were incubated for 45 minutes at 
room temperature and then rinsed in PBS. Sections were subsequently incubated for 
30 min at RT with a TRITC-labelled goat anti-rat antibody (Jackson ImmunoResearch 
Lab. Inc., West Grove, PA, USA) and rinsed in PBS and then incubated with a second 
TRITC-labelled antibody (donkey anti-goat, Jackson Immuno Research Lab. Inc.) 
resulting in a bright fluorescent signal of the vascular pattern. Tumour sections were 
scanned by a computer-controlled procedure [23]. Each tumour section was scanned 
separately for the perfusion marker and the vessel staining. After processing, the 
scanned sections were reconstructed into two composite images: one of the vascular 
structures and another of the perfused areas (Hoechst). When both images were 
combined the overlapping structures represented those vascular structures which 
were perfused by Hoechst at the time of injection (perfused vascular area) (Figure 
1). The relative vascular area (RVA) was expressed as the ratio between the surface 
area of all vascular structures and the total tumour surface [17,23]. The perfused 
fraction (PF) was calculated as the total area (pixels) of perfused vascular structures 
divided by the total area of all vascular structures [23].
Figure 1 Digitised images of sections of tumour E106 (left panel) and E102 (right 
panel), stained immunohistochemically for vessels (red) and hypoxia (green). The 
blue colour represents the perfusion marker Hoechst 33342. The E106 tumor shows 
extensive hypoxia complementary to the Hoechst dye in contrast to the E102 tumour 
where hypoxia is not present. Magnification 100x.
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Figure 2 Summary of the total number of genetic alterations for the well vascularised 
and poorly vascularised group. Open bars represent losses, closed bars represent 
gains. The vertical line indicates the number of losses or gains in each group. The 
chromosome arms are indicated at the bottom of the figure. In acrocentic chromosomes 
(13,14,15,21,22) only the q arms can be analysed by CGH, the Y chromosome is not 
analysed by CGH.
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After scanning the vascularisation and perfusion in the xenografts, the same sections 
were incubated overnight at 4°C to detect hypoxia with Rabbit-anti-pimonidazole 
(supplied by J. Raleigh, Department Radiation Oncology and Toxicology, UNC 
School of Medicine, Chapel Hill, USA), diluted 1:2000 in PBS + 1% BSA. The next 
day the sections were washed three times in PBS and incubated for 2 hours at room 
temperature with donkey-anti-rabbit-FITC in PBS-B (Jackson Immuno Research Lab. 
Inc) diluted 1:100. Staining for hypoxia was assessed semi-quantitively as strongly 
positive, positive or negative. For technical reasons, hypoxia could not be rated in 
E80 and E110.
Comparative genomic hybridisation
CGH was performed as previously described [24]. Briefly, normal DNA and tumour 
DNA were labelled with digoxigenin-dUTP (Boehringer Mannheim) and biotin-dUTP 
(Boehringer Mannheim) in a standard nick translation system, respectively. The 
pre-treated metaphase slides and the probes were denatured simultaneously and 
hybridisation was performed for three days. After hybridisation, the slides were washed 
stringently and the biotinylated DNA was detected using streptavidin-FITC and the 
digoxigenin-labelled DNA with sheep-anti-digoxigenin-TRITC. Chromosomes were 
counter stained with 4’-6-diamidino-2-phenylindole (DAPI) to identify the chromosome-
banding pattern. Adequate controls were included in all experiments [24].
RESULTS
The results of the assessment of angiogenesis, quantification of perfusion, the degree 
of hypoxia, growth rate and genetic changes in the 10 xenografts are summarised in 
Table 1. The RVA values measured on 8 sections from each tumour ranged from 0.07 
(E49) to 0.18 (E102). The perfusion rate ranged between 0.44 and 0.65. The tumours 
showed major differences in the degree of hypoxia (Table 1). Examples of typical 
patterns are shown in Figure 1: xenograft E106 shows extensive hypoxia whereas it 
is absent in the well vascularised E102.
Growth rate was constant within each line and passage, but showed major differences 
between the lines. Tumours E2 and E120 had slow growth rates; E49 and E98 had 
intermediate growth rates; E18, E34, E80, E102, E106 and E110 were fast growing 
tumours. The growth rates were not related to the RVA or PF (Table 1).
The profiles of genetic alterations are summarised in Table 1 and are described in 
detail by Jeuken et al. [15]. Briefly, all tumours had loss of the whole or parts of 
chromosome 10 and gain of chromosome 7 or 7p. Furthermore, amplification of whole 
chromosome 19 or 19p and loss of chromosome 13 as well as loss of chromosome 
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11 and gain of chromosome 8q were frequently found. E34 showed additional genetic 
alterations (loss of 1p and 19q) that are frequently found in oligodendroglial tumours 
[24], but these were not related to a specific vascularisation type.
On the basis of the RVA, two different vascularisation types of xenografts can be 
recognised (Table 1 and Figure 1). The poorly vascularised (pv) type has an RVA 
< 0.10 (E2, E34, E49, E98, E106). The well vascularised (wv) type has an RVA > 
0.10 (E18, E80, E102, E110 and E120). The pv type shows hypoxia whereas the wv 
tumours that could be evaluated are negative for the hypoxic marker. Mean RVA for 
the wv group was 0.14 (SD 0.03) and for the pv group 0.08 (SD 0.008). There was 
a significant difference in RVA between the pv and wv group (P < 0.01, Wilcoxon 
test). Interestingly, the PF was not significantly different between the wv and pv group 
(0.55, SD 0.08 and 0.62, SD 0,03 respectively). Figure 2 shows the sum of genetic 
alterations for each chromosome arm of the wv and the pv group. The pattern of 
genetic alterations was not clearly different between the pv type and wv type, but the 
pv group had a higher number of aberrations (88) than in the wv group (70). Growth 
rate was not related to the vascular type.
DISCUSSION
In diffuse astrocytic tumours, florid angiogenesis is associated with high-grade 
malignancy [4,16]. This angiogenic process is induced by hypoxia [8-10]. In addition, 
tumour angiogenesis may be upregulated by genes resulting from the genetic changes 
acquired during tumour progression [13].
Our previous study [19] showed that the chromosomal imbalances in these xenografted 
GBMs are similar to the original GBMs, as well as GBMs described by others [25,26], 
indicating that the GBM xenigraft lines are valid models from a genetic point of view. 
The CGH analysis of different passages indicated that xenografted GBMs, like original 
GBMs, show intratumoural genetic heterogeneity. 
By quantitative microscopic analysis, we found two patterns of vascularisation in 
GBM xenografts: well vascularised (wv) and poorly vascularised (pv). The pv/hypoxic 
xenograft group is marked by more numerous genomic aberrations (Figure 2). 
This pattern might represent either genetic heterogeneity between the xenografts 
or genetic instability induced by hypoxia [27]. No consistent single chromosome 
aberration separating the groups was observed, however. An association between 
single genetic aberrations and vascularisation were sought by scanning the human 
genomic database for chromosomal localisation of factors involved in angiogenesis;e.
g. platelet-derived growth factor-A (7p22) and B (22q12.3-13.1), platelet-derived growth 
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factor receptor (5q31-32), fibroblast growth factor 1 (5q31), 2 (4q25-27), 6 (12p13), 9 
(13q11-12), fibroblast growth factor receptor 3 and 4 (4p16.3, 5q35.1-ter), fibroblast 
growth factor beta receptor (1p33-32), transforming growth factor B1 (19q13.1-13.3) 
and B2 (1q41), VEGF-A (6p21-12), VEGF-B (11q13) and VEGF-C (4q34). By CGH 
analysis no correlation was found between genetic alterations in these chromosomal 
regions and angiogenic type in these xenografts, with the exception of gain on 1p 
(fibroblast growth factor beta receptor) and 19q (transforming growth factor B1) in 
two and three xenografts in the wv group respectively. In particular regions carrying 
the VEGF-A, VEGF-B and VEGF-C genes did not differ between the two types. 
Amplification of 6p21-12 (VEGF-A region) was seen in only one tumour. However, 
the extensive genomic alterations in the end phase of malignant progression make it 
difficult to find a pattern of genomic alterations. Also CGH has limitations with regard 
to sensitivity and detects only copy number changes larger than 2Mb [28]. CGH does 
not detect translocations or inversions, which are other mechanisms by which gene 
expression can be altered [29].
The existence of different vascular phenotypes of GBM xenograft lines can be 
explained in various ways. Firstly, GBMs show a major heterogeneity of the 
vascularisation within the tumour [17], and the wv xenograft lines could represent 
samples derived from foci of efficient angiogenesis. Secondly, the process of serial 
passaging of xenografts may result in the selection of angiogenic cell clones. However, 
the observation of line-specific and stable characteristics of vascularisation does not 
support this explanation [17]. Thirdly, the different vascular phenotypes of xenografts 
lines may represent differences between neoplastic cells in response to angiogenic 
factors, such as hypoxia.
In our opinion, the xenograft model with quantitative image analysis is a valuable 
model to study angiogenesis in GBMs as it quantifies the end-result of this process; 
i.e. the formation of capillaries by activated endothelial cells [2]. Angiogenesis in 
GBMs might be related to genetic aberrations, but requires further investigations. This 
can be accomplished by studying the xenografts in more detail. A study using area-
specific CGH has revealed focal genetic micro-heterogeneity in GBMs [30]. CGH can 
be used on microdissected tumour cells taken from areas with different angiogenic 
capacity. Furthermore, glioma cell clones can be analysed for their properties to induce 
angiogenesis [15]. Clones showing a strong capacity to induce angiogenesis can then 
be analysed by CGH and compared to clones without these properties for differences 
in genetic alteratons. The use techniques with a higher resolution like fluorescence in 
situ hybridisation (FISH) and single stranded conformation polymorphism (SSCP) for 
specific groups of genes is a strategy to further elucidate genomic alterations. These 
techniques could be used in addition to CGH, as they do not provide an overview of 
genomic alterations.
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In conclusion, two vascular phenotypes of xenografted GBMs were identified with 
respect to RVA and degree of hypoxia. Poorly vascularised tumours had more genomic 
alterations, but no unequivocal correlation between angiogenesis and patterns of 
genetic alterations as detected by CGH was established.
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ABSTRACT
In the World Health Organisation (WHO) classification of tumours of the nervous 
system, four main histopathological subtypes of medulloblastomas (MB), classic 
MB, desmoplastic MB, MB with extensive nodularity and advanced neuronal 
differentiation, and large cell/ anaplastic MB, as well as of ependymal tumours (ET), 
low-grade ependymoma, anaplastic ependymoma, myxopapillary ependymoma, 
and subependymoma, are recognised. Under the hypothesis that the microvascular 
architecture of tumours is a reflection of the histopathological subtype, we performed 
three-dimensional (3D) reconstructions of the microvasculature in MB and ET 
subtypes using computerised image analysis. In addition, we quantitatively assessed 
three microvascular parameters (vessel number, vessel area, vessel perimeter). 3D 
reconstructions showed a dense pattern of irregular vessels in classic and large cell 
MB. In desmoplastic MB and MB with extensive nodularity, the vessels were more 
unevenly distributed and organised around the nodular areas. Classic MB and large 
cell MB had on average the largest vessel area and perimeter. The highest number 
of vessels was seen in classic MB and MB with extensive nodularity. 3D analysis of 
ETs showed that low-grade ependymoma had larger but fewer vessels compared 
to anaplastic ependymoma, while myxopapillary ependymoma had a complex, 
heterogeneous pattern of vessels and subependymoma few but regular vessels. 
In ETs, the highest values for vessel number, vessel area, and vessel perimeter 
were found in anaplastic ependymoma and the lowest values in subependymoma. 
We conclude that our 3D reconstructions shed unprecedented light on the tumour 
vasculature in MBs and ETs and expect that such reconstructions are helpful tools for 
further studies on angiogenesis.
INTRODUCTION
Medulloblastomas (MBs) and intracranial ependymal tumours (ETs) are neuroepithelial 
tumours, mainly occurring in individuals younger than 16 years old. Spinal ETs occur in 
all age groups [1,2,3]. The World Health Organisation (WHO) classification of tumours 
of the nervous system distinguishes four main histopathological subtypes of MBs and 
of ETs. MB variants are classic MB, desmoplastic MB, MB with extensive nodularity 
and advanced neuronal differentiation, and large cell/anaplastic MB. ET variants are 
low-grade ependymoma (lgE; WHO grade II), anaplastic ependymoma (aE; WHO 
grade III), myxopapillary ependymoma (mpE; WHO grade I), and subependymoma 
(subE; WHO grade I) [3]. The MB subtypes mentioned above are all designated by the 
WHO as high-grade (grade IV) malignancies and so far are considered as belonging 
to the same spectrum. In the ET group, on the other hand, subE and mpE are different 
entities rather than belonging to the spectrum of lgE and aE.
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Treatment for MBs and intracranial lgEs and aEs is not yet based on histopathological 
features. However, some recent studies show that children with a large cell/ anaplastic 
MB have a poorer outcome [4,5], whereas children with a MB with extensive nodularity 
tend to fare better than children with other MB subtypes [6]. The prognostic significance 
of histological malignancy grade in lgEs and aEs is unclear [3]. MpEs generally have 
an indolent behaviour and do not need additional therapy after gross total resection. 
SubEs are often coincidental findings during autopsy, and only sporadically cause 
clinical symptoms [3,7].
There is a huge interest in the tumour vasculature as a potential target for anti-tumour 
therapy [8,9,10]. So far, however, knowledge about the tumour microvasculature 
in MBs and ETs is limited. Accurate visualisation of the microvascular network is 
important for a better understanding of tumour angiogenesis. We therefore performed 
three-dimensional (3D) reconstruction as well as quantitative analysis of 3 vascular 
parameters (vessel number, vessel area, vessel perimeter) in the main histopathological 
subtypes of MBs and ETs under the hypothesis that the histopathological subtype 
is reflected by the microvascular architecture. For 3D reconstruction, a recently 
developed technique was applied [11]. The 3D images of the tumour microvasculature 
were compared to those of normal cerebral neocortex, cerebral white matter, and 
cerebellar cortex and white matter.
MATERIALS AND METHODS
Tissues
Representative biopsy samples of a paraffin embedded classic MB, desmoplastic 
MB, MB with extensive nodularity, large cell MB, supratentorial lgE, posterior fossa 
aE, spinal mpE, and supratentorial subE, as well autopsy material of adult normal 
cerebral neocortex, cerebral white matter, cerebellar cortex, and cerebellar white 
matter were selected from the archives of the Department of Pathology, Radboud 
University Nijmegen Medical Centre. A special method was used to allow for cutting up 
to 60 serial sections of constant thickness and with minimal loss or distortion of tissue 
[11]. For 3D visualisation in this study, we investigated 45-60 serial 4 μm sections. 
The serial sections were stained for endothelial cells with a monoclonal antibody to 
CD34 (mouse monoclonal, 1: 750, Neomarkers, Fremont, USA). Immunostaining was 
performed using the avidin-biotin-complex method; the chromagen used to highlight 
vessels was 3.3’- Diaminebenzidine tetrahydrochloride (DAB), resulting in a brown 
product. In order to improve the signal to noise ratio during image acquisition, no 
counterstaining was used.
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3D visualisation
Computerised 3D visualisation of the vascular bed was performed as recently 
described by our group [11]. In short, 45-60 images of corresponding microscopic fields 
in subsequent tissue sections were digitally stored. A microscopic field (10 x objective, 
field size 0.74 mm2) was aligned as closely as possible with a rotating microscope 
stage, using an image overlay on the computer screen depicting the vascular profiles 
of the previous tissue section. After storage of an entire series of images, automated 
recognition of vascular profiles (image segmentation) was performed based on positive 
immunohistochemical staining of endothelial cells. Results of segmentation for each 
microscopic field were shown as an overlay in the original image on a computer screen 
for visual inspection and, if necessary, interactive correction. Image registration was 
fine-tuned automatically using an affine image transformer, which corrects for shifts, 
rotations and stretching in x and y direction. Finally, 3D visualisation was performed 
using a marching cube algorithm, resulting in static images of the 3D reconstruction. 
Of each tumour, two representative microscopic areas were analysed in this way. 
Cerebral neocortex, cerebral white matter, cerebellar cortex, and cerebellar white 
matter of a normal human brain obtained by autopsy, served as control tissues.
Quantitative analysis of vasculature
Quantitative analysis of the vasculature was performed for each tumour in a single 
tissue section halfway the series of CD34-stained serial sections following the method 
we described earlier [12]. In addition, the same was done on normal cerebellar and 
cerebral cortex and white matter. In the section used for quantitative analysis 8-20 
microscopic fields (10 x objective, field size 0.74 mm2) were analysed and in these 
fields the vessel number, vessel area, and vessel perimeter were calculated.
RESULTS
Figure 1 shows a compilation of haematoxylin and eosin (H&E) stained sections 
(first row), CD34 stained areas highlighting vasculature (second and fourth row) 
and 3D reconstructions of the microvasculature in these areas (third and fifth row) 
in four subtypes of MB and ET. For comparison, similar images of normal cerebral 
neocortex, cerebral white matter, cerebellar cortex, and cerebellar white matter are 
included. Figures of normal cerebral neocortex and white matter were obtained with 
kind permission from Gijtenbeek et. al [11]. Figure 2 shows the results of quantitative 
assessment of vessel number, vessel area, and vessel perimeter of the cerebral 
neocortex, cerebral white matter, cerebellar cortex, and cerebellar white matter, MBs 
and ETs, that were used for 3D reconstruction of the microvasculature.
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Normal cerebral and cerebellar tissue
3D reconstruction of the cerebral neocortex, cerebral white matter, cerebellar cortex, 
and cerebellar white matter revealed a regular vascular pattern with little variation in 
the vessel diameter. Compared to normal cerebral and cerebellar white matter, the 
cerebral neocortex and the cerebellar cortex had a more intense, somewhat more 
delicate, but regular vascular pattern (Figure 1). The microvascular parameters in 
cerebral neocortex and cerebellar cortex were in the same range for vessel area 
and perimeter, while vessel number was higher in cerebellar cortex. Compared to 
normal cerebral and cerebellar white matter, these parameters in cerebral neocortex 
and cerebellar cortex were more variable. In cerebral and cerebellar white matter the 
vessel number, vessel area, and vessel perimeter were comparable and relatively 
low, with little variation from field to field (Figure 2).
MBs
With 3D reconstruction, classic MB had a dense, more or less evenly distributed 
microvascular pattern, the vessels showing a variable diameter. In desmoplastic 
and extensive nodularity MBs, the blood vessels showed an uneven distribution with 
organisation around the nodular (‘pale island’) zones. Large cell MB blood vessels 
showed an uneven distribution and the formation of tufts. Compared to normal 
cerebellar cortex and white matter (i.e. the tissue in which MBs occur), more variation 
was present for all microvascular parameters in all MB subtypes. However, the values 
for the parameters were generally still in the range of normal cerebellar cortex or white 
Figure 1
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Figure 1 Haematoxylin and eosin (H&E) stained histological sections (original 
magnification x 100), 2-dimensional images (immunohistochemical (CD34) staining 
for endothelial cells) and 3D reconstructions of the vasculature of cerebral neocortex, 
cerebral white matter, cerebellar cortex, cerebellar white matter, classic MB, 
desmoplastic MB, MB with extensive nodularity, large cell MB, supratentorial lgE, 
posterior fossa aE, spinal mpE, and supratentorial subE. The arrows in the H&E 
stained sections of desmoplastic MB and MB with extensive nodularity indicate 
nodular (‘pale island’) zones.
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Figure 2 Vessel number, vessel area, vessel perimeter of cerebral neocortex, cerebral 
white matter, cerebellar cortex, cerebellar white matter, classic MB, desmoplastic 
MB, MB with extensive nodularity, large cell MB, supratentorial lgE, posterior fossa 
aE, spinal mpE, supratentorial subE. Vessel number - number of complete vascular 
profiles in a field; each vascular profile demarcated from the surrounding tissue by a 
continuous basement membrane was considered as a separate blood vessel. Vessel 
number is the vascular density of the field. Vessel area - sum of areas of all individual 
vascular profiles in a field in mm2. Vessel perimeter - sum of perimeters of all individual 
vascular profiles in a field in mm [11]. Abbreviations; ext. nod. = extensive nodularity, 
m. = matter, meas. = measured.
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matter. In occasional microscopic fields, the vessel number in large cell MB was lower 
than in normal cerebellar white matter, while in some fields the vessel area and vessel 
perimeter in classic and large cell MB exceeded those of normal cerebellar cortex. 
Median vessel area and perimeter were higher in classic and large cell MB than in 
desmoplastic and extensive nodularity MB, while median vessel number were higher 
for classic and extensive nodularity MB. Variation for vessel area and perimeter was 
most extensive in classic and large cell MB. Variation for vessel number was largest 
in classic MB and MB with extensive nodularity.
ETs 
3D reconstructions of the ETs showed that lgE had fewer but larger vessels as 
compared to aE. MpE contained a complex, irregular and partly dense vascular pattern, 
while subE showed relatively few but regular vessels. The vascular parameters in 
low grade and anaplastic ET were comparable, showed much more variation than 
in normal cerebral and cerebellar tissue, and while vessel number and perimeter 
were in the range of normal brain tissue, the vessel area was found to be much 
higher. In contrast, in subE all three vascular parameters were lower than in normal 
cerebral and cerebellar white matter. The mpE showed a relatively high variation for 
vascular parameters over the different fields, in some of them the values for these 
parameters were in the range of subE, while in others the value for vascular area and 
perimeter (but not for vessel number) exceeded that of normal cerebral neocortex and 
cerebellar cortex.
DISCUSSION
Studies on angiogenesis in tumours of the CNS generally focussed on astroglial 
tumours (for recent review, see [10]), and relatively little attention has been given to this 
process in MBs and ETs. Some studies in the latter tumours investigated angiogenesis 
as a prognostic factor for survival, or as a possible target for therapy [13-18]. Thus 
far, the correlation between survival and vascular pattern is unclear for MBs and ETs. 
In a study of 23 patients with MBs, Ozer et al. [16] found high vessel density to be 
a significant unfavourable prognostic factor. This contrasts with another study of 78 
children with MBs by Grotzer et al. [17], in which vessel density was not predictive of 
outcome. Nevertheless, these authors considered MBs as good candidates for anti-
angiogenic strategies [17]. In a study of 112 cerebral ETs, progression-free survival 
time was found to be significantly shorter for VEGF and EGFR positive lgEs, as 
compared to VEGF and EGFR negative lgEs [14]. In another study of 100 intracranial 
ETs, markers for hypoxia (carbonic anhydrase 9, hypoxia-inducible factor 1 alpha, 
and VEGF) were not related to outcome [18]. In a study of supratentorial primitive 
neuroectodermal tumours and MBs, the spatial organisation of tumour vessels was 
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described to allow for differentiation between different prognostic subtypes [19].
Our study is the first on 3D reconstruction of microvasculature in MBs and ETs. 
We conducted this study with the hypothesis that the histopathology of different 
subtypes is reflected by a difference in the tumour microvasculature and compared 
the architecture of the tumour vessels with that of normal cerebral and cerebellar 
tissue. For MBs, classic and large cell MBs had a denser vasculature pattern than 
desmoplastic MB and MB with extensive nodularity. In the latter two MB types we 
found vessels to be organised around the nodular, reticulin-free zones. In fact, this 
is what one would expect knowing that the nodules in these subtypes are classically 
described as reticulin-free ‘pale islands’ while the wall of blood vessels does contain 
reticulin. The vasculature of ETs varied widely. The most dense pattern was seen in 
aE, while at the other end of the spectrum subE only showed few but regular vessels. 
The vasculature of mpE, which is a WHO grade I tumour, had a distinct irregular and 
partly dense pattern. While mpEs are classified together with lgEs and aEs in the 
category of ETs, their typical histopathology, radiology, and genetic characteristics 
indicate that mpEs form a separate entity [19,20]. Although variation for the vascular 
parameters was high in MBs, these parameters were generally in the range of normal 
cerebellar cortex and white matter. Of the vascular parameters of ETs, only mean 
vessel area was larger for lgE, aE, and mpE, as compared to normal cerebral and 
cerebellar tissue. Variation of vascular parameters was high for all ETs, except for 
subE. The subE had less vessels than normal cerebral tissue.
For several reasons, our present 3D and quantitative results should be interpreted 
with some caution. First, in the one representative tumour that was investigated in 
each category, only two microscopic areas were used for 3D reconstruction and 8-20 
microscopic fields were used for quantitative analysis. It would be overly optimistic 
to expect that this study fully accounts for intra- and intertumoural heterogeneity. 
Furthermore, it is important to realise that, dependent on the growth pattern of the (brain) 
tumour studied, the intratumoural vessels may be newly formed vessels, incorporated 
pre-existent vessels, or a combination of both [21]. Especially in infiltrative tumours 
like MBs, the majority of the tumour vessels may in fact be incorporated vessels, while 
in ETs (that generally show a more expansive growth pattern) the vast majority of the 
tumour vasculature may well be derived from neovascularisation, especially so in the 
subE which typically grows as a solid, exophytic tumour in the ventricular system. 
Whether brain tumours with vascular parameters within the range of normal cerebral 
and cerebellar tissue are good candidates for anti-angiogenic therapies depends on 
the actual degree of neovascularisation. Anti-angiogenic therapies are considered 
effective only if newly formed vessels are targeted [22]. Even in the absence of newly 
formed vessels, however, microenvironmental factors may cause vascular changes 
like vasodilatation. In the quantitative part of our study the latter would result in (areas 
with) increased vessel area and vessel perimeter without an increase in vessel number. 
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Interestingly, our quantitative analysis revealed a somewhat higher vessel number in 
normal cerebellar cortex than in normal cerebral neocortex. This finding might be 
explained by the fact that the areas selected for quantitative analysis of cerebellar 
cortex were all located in the granular layer. As this layer contains an extremely high 
number of (small) neurons, one can imagine that the demand for oxygen and nutrients 
(and therefore the vascular density) is especially high in this zone.
In conclusion, 3D reconstructions contribute to a better understanding of the true aspect 
of tumour vasculature [11]. We found a spectrum of patterns in the 3D reconstructions 
of the microvasculature in MB en ET subtypes, ranging from intensely to sparsely 
vascularised. Our results clearly show the disorganised and tortuous nature of the 
vasculature of some MB and ET subtypes, aspects that are more difficult to appreciate 
in 2-dimensional sections or by quantitative analysis. In the future, 3D reconstruction 
of the tumour microvasculature in combination with markers identifying newly formed 
vessels will be of help to determine the degree of angiogenesis dependency of 
tumours. Unfortunately, unequivocal markers for such newly formed tumour vessels 
are not yet available. In animal models, 3D reconstructions can also be used to 
monitor the effects of anti-angiogenic treatment and to test hypotheses concerning 
the pathobiological significance of different stimuli or inhibitors of this process.
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ABSTRACT
Low-grade ependymomas (lgEs) and myxopapillary ependymomas (mpEs) are the 
most common primary tumours of the spinal cord. Recurrence-free survival depends 
on local control of the tumour. The value of additional radiotherapy (RT) is still a 
matter of debate. The aim of this retrospective study was to analyse radiotherapy, 
surgery and the preoperative state with regard to recurrence rate and long-term 
neurological outcome. Sixty patients with spinal lgEs (40) and spinal mpEs (20) were 
included. According to local policy, 14 patients who underwent total resection and 
20 patients with incomplete resection were irradiated postoperatively. Total resection 
was achieved in 34 of the 60 tumours. Preoperative state and long-term outcome was 
assessed according to a previously published scale. When postoperative RT was 
applied after partial resection, only 3 of 11 lgEs and 1 of 9 mpEs recurred. All partially 
resected non-radiated lgEs (n = 3) and 2 of the 3 partially resected non-radiated 
mpEs recurred. There was no recurrence after total resection. Only one of 6 patients 
with disseminated mpEs had clinical symptoms caused by the disseminated tumour. 
Long-term neurological outcome was related to preoperative conditions with no 
difference between partially and totally resected tumours. Our study shows that RT is 
only beneficial for partially resected lgEs and mpEs. Local recurrence-free survival of 
spinal lgEs and mpEs is obtained by total resection. Long-term neurological outcome 
is related to preoperative conditions. Seeding is seen in mpEs and does not cause 
clinical symptoms in most of the patients.
INTRODUCTION
Although ependymomas are relatively rare, they are the most common primary 
tumours of the central nervous system arising in the spinal cord and comprise 
60% of spinal primary tumours [1]. They originate from the ependymal cells lining 
the ventricular system and the central canal in the spinal cord. Whereas 69% of 
the intracranial ependymomas occur in children, most spinal ependymomas (96%) 
are seen in adults [2]. The vast majority of spinal cord ependymomas belong to the 
cellular low-grade ependymomas (lgEs) (WHO grade II) or myxopapillary (mpEs) 
(WHO grade I) histologic subtype. LgEs are found throughout the spinal canal and 
can be situated both intra- and extramedullary. MpEs are located extradurally in the 
sacral coccygeal region, and intradurally in the conus-cauda region and are classified 
as extramedullary tumours [2]. Spinal ependymomas are generally tumours of low-
grade malignancy with little infiltrative potential [3-8]. However, mpEs have a potential 
for dissemination within the spinal canal [9]. An unknown percentage of mpEs tend 
to disseminate within the spinal canal despite the low malignancy grade [9-11]. No 
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agreement exists on the management of these disseminated tumours as it is not 
known if they cause clinical symptoms.
For spinal ependymomas, recurrence-free survival depends on local control of the 
tumour [1,8,12,13]. Subtotal removal results in local recurrence in up to 50-70% 
[13,14]. Total resection provides the best long-term local control and reduces the 
risk of recurrence to 5-10% [6,8,12]. However, complete removal of the tumour is not 
possible in 57-76% of the cases because of the risk of serious neurological deficits 
[6,15,16]. Whether radiotherapy (RT) following subtotal resection of primary low-grade 
spinal ependymomas is beneficial, is a matter of debate [17]. Although accumulated 
data suggest that irradiation may be beneficial, most series are limited by a small 
number of patients, lack of clinical follow-up and the absence of a trial with matched 
controls treated without irradiation [18-22].
We performed a retrospective study of 60 patients with 40 primary spinal lgEs and 
20 primary spinal mpEs. We determined the effects of postoperative RT, surgical 
results (total versus partial resection) and preoperative state on local recurrence and 
long-term neurological functional outcome. In addition, the management of intraspinal 
seeding of mpEs is discussed.
PATIENTS AND METHODS
Patient population and demographics
Sixty-three patients with 72 tumours from 2 hospitals (University Medical Centre 
St Radboud, Nijmegen, The Netherlands; St Elisabeth Hospital, Tilburg, The 
Netherlands) who were treated for spinal ependymomas between 1985 and 2000 
were analysed retrospectively. The subependymomas, anaplastic ependymomas (n 
= 3) and recurrences (n = 9) were excluded from analysis. Information was obtained 
from the medical records about clinical presentation, imaging, operative procedures, 
neuropathological diagnosis and long-term neurological outcome. Preoperative state 
and long-term neurological outcome was assessed according to the McCormick scale 
(Table 1) [8]. Diagnosis was made according to the WHO classification [10]. The 
mean age at diagnosis was 42 years for the lgE patients (range 13-82 years, 25 
males, and 15 females) and 30 years (range 14-57 years, 9 males, and 11 females) 
for the mpE patients. Preoperative diagnosis was made by MRI (n = 45) and CT-
myelo (n = 15). The time between onset of symptoms and diagnosis of the primary 
tumours varied from a few weeks to 10 years for both lgEs and mpEs. Forty (66%) 
of the primary ependymomas were classified as lgEs (WHO grade II) and 20 (33%) 
as mpEs. All mpEs were located extramedullary in the conus-cauda equina and filum 
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terminale. Table 2 gives an overview of the site of the primary spinal lgEs and mpEs. 
The follow-up ranged from 3 to 15 years (mean 7 years).
Course of treatment
Patients were treated with an attempted total resection of the ependymoma through a 
posterior approach. Total resection was defined as macroscopic complete resection. 
Participating hospitals differed with regard to the indication for radiotherapy (RT). One 
centre offered RT to all patients, whereas the other centre only irradiated some of 
the patients with partially resected ependymomas. Decisions to irradiate in the latter 
group were made on individual grounds. As some physicians were not convinced of the 
beneficial effects of RT, some patients with partially resected tumours were not irradiated 
postoperatively. RT was given in a dose of 45 to 50 Gy locally with a wide margin in 
daily fractions of 1,8-2,25 Gy. Elective whole spinal cord radiation was not given. All 
recurrences were local and in the radiation field. Treatment consisted of resection and 
RT. In one case treatment was omitted due to the poor condition of the patient.
RESULTS
Of the 14 lgEs cases with partial resection, 11 received RT. All three non-irradiated 
partially resected lgEs recurred, against 3 of the 11 radiated partially resected lgEs 
(27%) (p < 0.001). Of the 9 irradiated partially resected mpEs only one recurred, 
against 2 of the 3 non-irradiated partially resected mpEs (P < 0.001) (Table 3). No 
recurrences occurred after macroscopic total resection.
Total resection of the primary tumour was achieved in 26 of the 40 lgEs (65%) and in 
8 of the 20 (40%) mpEs.
 LgEs MpEs
Location (Number of patients) (Number of patients)
  Total resection Partial resection Total resection Partial resection
Cervical  
Cervicothoracic 2 3
Thoracic 6 1
Thoracolumbar 3 3 4 8
Lumbosacral 11 3 4 4
Table 2 Location of primary spinal lgEs and mpEs.
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The long-term neurological morbidity was related to the preoperative neurological 
condition. Patients with no or minor neurological deficits preoperatively rarely deteriorated 
after surgery. The extent of resection did not have an impact on neurological status 
(Table1). One patient with a total resected tumour suffered from myelomalacia due to 
radionecrosis one year after being irradiated with 28 fractions of 1,80 Gy.
Six patients with primary mpEs had dissemination of the tumour within the spinal canal. 
For two of these patients in whom the original diagnosis was made by CT-myelo, this 
was found by MRI during the follow-up. These disseminated tumours caused clinical 
symptoms (a radicular syndrome) in only one patient. He had undergone a partially 
resection without additional RT 6 years before, and had clinical symptoms from the 
local recurrence as well as the disseminated tumour.
DISCUSSION
On the basis of small, largely uncontrolled studies the value of RT after partial 
resection of spinal lgEs and mpEs is difficult to establish [9,21,22]. Despite these 
limitations, the accumulated data suggest that irradiation may be beneficial [14,20,21]. 
In our study, RT significantly reduces local recurrence both for lgEs and mpEs. No 
recurrences occurred after total resection, which is in concordance with other studies 
[6,8]. We conclude that RT is only indicated for partially resected lgEs and mpEs, but 
not after macroscopic gross total resection. Because these patients survive for many 
years, they are at risk of late complications of RT. As recurrences of these tumours 
usually occur at the primary site within the radiation field, craniospinal irradiation is 
not considered useful [22].
 LgEs (n = 40) MpEs (n = 20)
 Total resection Partial resection Total resection Partial resection
  (n = 26) (n = 14) (n = 8) (n = 12)
Male/ Female 17/ 9 8/ 6 3/ 5 6/ 6
Age (years) 45 38 36 27
-Range 13-82 17-68 14-57 16-40
Radiotherapy (+/-) 10+ 16- 11+ 3- 4+ 4- 9+ 3-
Recurrences 
(number/ %) 0 0 3 (27%)* 3 (100%)* 0 0 1 (11%)* 2 (66%)*
Mean time to 
recurrence (years)   7 10   10 8
Table 3 Patients’ and treatment characteristics for the primary lgEs and mpEs,* 
(P < 0.001).
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The role of surgery in the management of spinal lgEs and mpEs has been well 
documented. It is widely accepted that surgical resection is the treatment of choice 
and that radical removal alone controls the disease. Complete removal of the tumour, 
however, is often impossible because of the risk of serious neurological deficits such 
as paralysis or severe sensory disturbances (6,15,16). Most studies claim a total 
resection rate for spinal lgEs and mpEs of 57-76% [3,9,12,23].
In our study, the strongest predictor of long-term functional outcome for both lgEs and 
mpEs was preoperative functional status. Patients with severe neurological deficits 
were the least likely to improve postoperatively. The latter is in accordance with 
previous reports [6,8]. Patients with a partial resection were on average not worse off 
as compared to those with completely resected tumours.
Interestingly, six patients with mpEs (30% of mpEs) had intradural seeding, causing 
clinical symptoms in only one patient. Although mpEs have a low proliferation rate and 
are designated as WHO grade I, they do have a significant potential for dissemination 
through the spinal canal [9]. This might be partly caused by their extramedullary location, 
favouring seeding of loose tumour cells, and is not considered a sign of aggressive 
tumour behaviour. In the past, seeding of mpEs has been reported sporadically, most 
often within the spinal canal [11]. Due to the use of MRI in the majority of patients, we 
found a higher incidence of intraspinal seeding. They are difficult to operate on due 
to their small size and usually stay unchanged even after years of follow-up. When 
showing symptoms, total resection is the treatment of choice.
In conclusion, our study shows that recurrence-free survival of spinal lgEs and mpEs 
is determined by total resection, and that RT has a beneficial effect on recurrence-
free survival only in partially resected tumours. Furthermore, postoperative clinical 
outcome is largely determined by the preoperative morbidity and is not different for 
patients with totally resected tumours as compared to those with partially resected 
tumours. Local seeding is almost exclusively seen in mpEs. In mpEs, this phenomenon 
is relatively frequent but does not cause clinical symptoms in the majority of patients 
and treatment of these seeded tumours is indicated only when they cause clinical 
symptoms.
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Summary and general discussion
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Tumours of the central nervous system (CNS) are the leading cause of cancer related 
death in patients under 16 years. These tumours differ in histopathological spectrum, 
localisation and behaviour from adult CNS tumours. In addition, the treatment requires 
special attention with regard to the need to preserve a normal cognitive and physical 
development of the child. Medulloblastomas (MBs) and ependymal tumours (ETs) 
account for 21-42% of CNS tumours in children. In this thesis, some novel molecular, 
morphological, and prognostic aspects of MBs and ETs are presented.
In chapter 1, an overview is given of MBs and ETs. Epidemiologic data, clinical 
symptoms, radiological, histopathological and molecular diagnostic features are 
summarised. The different histopathological subtypes of MBs and ETs and their clinical 
behaviour are described. The most common cytogenetic abnormalities as detected by 
karyotyping, loss of heterozygosity (LOH), comparative genomic hybridisation (CGH), 
and ploidy studies in MBs and ETs are presented. In all patients, surgery is the initial 
step with gross total resection as its aim. For both MBs and ETs, gross total resection 
is the most important prognostic marker for disease-free survival. Further therapeutic 
options for patients with MBs, based on stratification of patients into ‘average-risk’ 
and ‘high-risk-groups’ are presented. For patients with ETs, the role of radiotherapy 
(RT) and chemotherapy (ChT) is discussed. The treatment of very young children 
(under the age of three) with MB and ET remains a major challenge as craniospinal 
irradiation is avoided because of late adverse neurocognitive and neuroendocrine 
sequelae. The outcome after a recurrence of MBs and intracranial ETs is generally 
poor, and no standard treatment at this point is available yet. About one-third of ETs is 
localised in the spinal cord; these tumours generally carry a good prognosis.
In chapter 2 we describe genetic alterations as detected by CGH in MBs. Ten MB 
biopsies and one MB cell line were examined to investigate if genetic alterations 
can be used as a prognostic factor. One amplification site on chromosome 8q24 
was detected in the cell line corresponding to the known amplification of the MYCC 
gene in this cell line. The gain of 2p21-24 in two tumours was shown to represent 
amplification of the MYCN gene by Southern blot hybridisation and fluorescence in 
situ hybridisation. No specific pattern of genetic alterations was associated with the 
clinical behaviour of the 10 tumours. Other investigators (describing a total of 150 
MBs) also found a spectrum of non-random genomic losses and gains. Our results 
were not completely concordant with cytogenetic analysis, probably due to inherent 
weaknesses of both procedures. Cytogenetic analysis of solid tumours evaluates 
only a limited number of cells. In addition, CGH detects only changes involving loss 
or gain of DNA, implicating that translocations, inversions, and multiploidy cannot 
be detected by CGH as equal amounts of tumour and control DNA are used in the 
experiments.
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Chapter 3 contains a study correlating distinct genetic subtypes of ETs with patient 
age and tumour localisation. So far, clinical studies have revealed that postoperative 
survival depends on age, tumour localisation, and extent of tumour resection. 
However, it is well established that tumour localisation and age are interrelated. 
Patients with spinal ETs are on average 40 years, whereas ETs in the posterior 
fossa are predominantly found in children. The genome of 20 ETs was screened for 
chromosomal imbalances by CGH. Loss of chromosome 22q (75%), 10q (65%), 21 
(50%), and 16p (50%) were the most frequently detected aberrations. In adults, spinal 
ETs relatively often showed gain of chromosome 2, 7, 12, and loss of 14q, posterior 
fossa ETs loss of chromosome 22, and supratentorial ETs loss of chromosome 9. 
Preference of some chromosomal imbalances for either paediatric or adult ETs were 
seen, the most striking being gain of chromosome 9 and loss of chromosome 6 in adult 
posterior fossa ETs. The genetic background of ETs is complex and partly correlated 
with tumour localisation, histopathological subtype and age of the patient.
In the study described in chapter 4, we investigated the inverse correlation we 
observed before between number of genetic aberrations (determined by CGH) and 
WHO malignancy grade in ET at the ploidy level. We found aneuploidy or tetraploidy 
to be common in the group of myxopapillary ependymomas (mpEs) and much less 
frequent in low-grade ependymal tumours (lgEs) and anaplastic ependymomas 
(aEs). Tumour material for CGH was available in about half of these tumours, and 
revealed the highest number of genetic aberrations in the mpEs, a lower number in 
lgEs and the lowest number in aEs. Interestingly, aEs contained fewer aberrations 
than the lgEs. Generally, malignant progression involves accumulation of genetic 
aberrations. Our findings, however, suggest that different genetic pathways exist for 
lgEs and aEs. Similarly, the mpEs, defined as a grade I malignancy according to the 
WHO classification, showed an extensive array of genomic aberrations. These results 
confirm that mpEs are distinctly different from lgEs and aEs at the genetic level and 
that extensive genomic alterations and aneuploidy in ETs are not in themselves an 
indicator of malignant behaviour, c.q. adverse prognosis.
In chapter 5, we describe a study about the relevance of insulin-like growth factors 
(IGFs) in MBs. IGFs are small polypeptide mitogens that resemble pro-insulin in 
structure. Through binding to the IGF-I receptor, they elicit growth promoting and 
anti-apoptotic effects. IGF-I is considered to mediate many of the growth promoting 
actions of growth hormone, whereas IGF-II acts as an autocrine growth and motility 
factor during prenatal growth and development. The expression patterns of IGF-I and 
-II mRNA in 14 MBs of 12 children and 2 adults were studied. In all cases, tumour cells 
showed abundant expression of IGF-I mRNA. Nine tumours showed significant IGF-II 
expression. In these tumours, the hybridisation signal almost exclusively co-localised 
with a sub-population of Ki-M1P positive cells that were identified as microglia cells 
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with a ramified morphology. Probably, during the transformation from the resting 
ramified towards the amoeboid morphology (or vice versa) IGF-II mRNA expression 
is temporarily induced. The induction of IGF-II mRNA expression by these cells in 
MBs could theoretically exert mitogenic and anti-apoptotic effects on adjacent tumour 
cells, but the exact meaning of this phenomenon needs further elucidation. These 
results support the view that IGF-I and -II are involved in the development and growth 
of MB, and that the IGF system is a potential target for therapy.
Chapter 6 and 7 are studies on tumour vasculature. Angiogenesis is considered of 
vital importance for the growth of solid tumours and metastases, and may therefore 
constitute a target for anti-cancer therapy. The knowledge of the mechanisms of 
angiogenesis is of importance for the further exploration of anti-angiogenic therapy. 
Tumour angiogenesis occurs as a result of both local tissue conditions (especially 
hypoxia) and specific genetic alterations acquired during oncogenesis.
Chapter 6 describes an investigation into the correlation between vasculature and 
genetic aberrations (as detected by CGH) in subcutaneous glioblastoma multiforme 
(GBM) xenograft lines, growing in mice. The prognosis of patients with a GBM is 
determined by local growth of their tumour. GBMs are histologically characterised 
by striking microvascular proliferation, which constitutes a target for new anti-cancer 
therapies. Angiogenesis is thought to be regulated by peptides, produced by tumour 
cells in reaction to local hypoxia. Alternatively, tumour angiogenesis may be caused by 
specific genetic alterations acquired during oncogenesis. The striking heterogeneity of 
the microvasculature in GBMs might be related to genetic heterogeneity within a GBM. 
To analyse the relationship between genetic aberrations and tumour angiogenesis, 10 
GBM xenografts were analysed by CGH. The 10 xenograft lines differed in vascular 
pattern, ranging from well to poorly vascularised. In this model, there was a trend of 
poorly vascularised tumours having more genetic alterations. However, there was 
no unequivocal correlation between vasculature, growth rate and patterns of genetic 
alterations in this tumour type. 
Chapter 7 is a study describing the three-dimensional (3D) reconstruction of the 
microvasculature in MB (classic MB, desmoplastic MB, MB with extensive nodularity, 
large cell MB) and ET histopathological subtypes Low-grade ependymoma (lgE), 
anaplastic ependymoma (aE), myxopapillary ependymoma (mpE), subependymoma 
(subE). It concerns a pilot study in which one sample of each histopathological 
subtype is examined. 3D reconstructions were performed by applying a new technique 
using computerised image analysis and reconstruction. In addition, we assessed 
vessel number, area, and perimeter, in each of these tumours. 3D reconstruction of 
the vasculature of MBs showed a dense pattern of irregular vessels in classic and 
large cell MB, whereas in desmoplastic MB and MB with extensive nodularity the 
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microvasculature was more unevenly distributed and organised around the nodular 
areas. Median vessel number, area, and perimeter were in the range of cerebellar 
cortex and white matter, with the exception of a higher vessel area in some areas 
of classic MB and large cell MB. 3D analysis of ETs showed that lgE had fewer, 
but larger vessels as compared to aE, while mpE had a complex, irregular pattern 
of vessels. SubE had few but regular vessels. In ETs, the highest values for vessel 
number, area, and perimeter were found in aE and the lowest values in subE. 3D 
vasculature reconstructions give additional insight in the tumour microvasculature 
and gives direction for further research.
In chapter 8, a retrospective clinical study on the value of additional RT for spinal lgEs 
and mpEs in adults and children is presented. Recurrence-free survival depends on 
local control of the tumour. The value of additional RT after surgery is still a matter 
of debate. The aim of this retrospective study was to analyse the preoperative state, 
surgery and RT, with regard to recurrence rate and long-term neurological outcome. 
Forty patients with spinal lgEs and 20 patients with mpEs were analysed. According 
to local policy in different hospitals, 14 of 34 patients who underwent total resection 
and 20 of 26 patients with incomplete resection were irradiated postoperatively. There 
was no recurrence after total resection, with or without RT. All partially resected non-
radiated lgEs and 2 of the 3 partially resected non-radiated mpEs recurred. When 
postoperative RT was applied after partial resection, only 3 of 11 lgEs and 1 of 9 
mpEs recurred. We concluded that local recurrence-free survival is obtained by total 
resection, that RT is only beneficial for partially resected tumours, and that long-term 
neurological outcome is related to preoperative conditions.
Implications for future research
Progress in the treatment of patients with MBs and ETs can only be achieved by a 
system of stratification according to prognostic and predictive factors of these tumours. 
Such a classification consists of a better combination of clinical, histopathological, 
molecular, genetic, and vascular features. The ultimate goal is ‘tailor-made’ treatment, 
in which patients with the most aggressive tumours receive the most intense therapy, 
while children with less aggressive tumours are treated as effectively but will be 
spared the late sequelae related to extensive treatment. It is clear that it is of utmost 
importance to determine reliable, reproducible prognostic factors. Gradually, more 
prognostic and predictive factors are becoming available to help us find a robust 
subdivision in the seemingly chaotic heterogeneous pool of MBs and ETs. Recent 
trials have shown that the large cell/ anaplastic histopathological variant of MB is 
associated with a poor prognosis [1]. At the molecular level, loss of 17p13.3, and/ 
or MYCC/MYCN amplification in MBs are also associated with a poorer outcome 
[1]. IGF-I and -II in MBs are of importance for tumour growth, but their prognostic 
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value needs further investigation [2]. So far, no study on ETs has provided prognostic 
molecular markers that reliably predict survival or tumour recurrence [3]. Large CGH 
studies suggest an association between gain of 1q and a worse clinical outcome [4,5]. 
The studies in this thesis have shown that histopathological ET subtypes differ with 
regard to genetics, ploidy, and vascular pattern. Larger groups of patients with ETs 
are needed to further improve stratification, optimising treatment accordingly.
One way to further investigate the associations between histopathological subtype, 
growth rate of the tumours, vasculature and genetic alterations is to use xenograft 
models. However, care should be taken that such models mimic the human intracerebral 
or intracerebellar situation as much as possible. In such models, the impact of new 
pharmacological, radiation, and anti-angiogenic therapies on vasculature, growth 
rate, and relapse rate of the tumour can be investigated.
The successful translation of angiogenesis inhibitors to clinical application depends 
on our understanding of the angiogenetic process [6]. Our studies have corroborated 
the importance of further studies of the vasculature in MBs and ETs, as it appears 
that specific patterns are associated with subtypes of tumours. Our findings therefore 
urge at further studies on the interaction of the tumours and bloodvessels at the level 
of metabolism and genetics. Furthermore, 3D reconstruction of the vasculature with 
markers for new versus pre-existent vessels could help to determine which vessels 
are actually a target for anti-angionetic therapy. Such studies will pave the way to 
pharmacotherapeutical trials aimed at reduction of tumour growth.
In conclusion, the findings of the studies presented here have shed some new light on 
the pathophysiology of MBs and ETs, and can serve as a basis for further exploration 
of their molecular, genetic and vascular characteristics. This will hopefully ultimately 
lead to more ‘tailor made’ therapies, optimising therapeutic effect and minimising 
damage to the cognitive and physical development of children with such tumours.
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Samenvatting en discussie
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Tumoren van het centrale zenuwstelsel (CZS) zijn de belangrijkste doodsoorzaak 
bij kinderen met kanker. Deze tumoren verschillen in histopathologisch spectrum, 
localisatie en beloop van tumoren op de volwassen leeftijd. Medulloblastomas (MBs) 
en ependymale tumoren (ETs) vormen in deze groep het belangrijkste deel (21-42%). 
De behandeling van deze CZS tumoren is moeilijk omdat de mentale en lichamelijke 
ontwikkeling nog niet voltooid is en beschadigd kan worden door de therapieën. In dit 
proefschrift worden nieuwe moleculaire, morfologische en prognostische aspecten 
van MBs en ETs besproken.
In hoofdstuk 1 wordt een overzicht gegeven van MBs en ETs. Epidemiologische 
gegevens, klinische symptomen, radiologische, histopathologische en moleculair 
diagnostische procedures worden samengevat. De verschillende histopathologische 
subtypes van MBs en ETs en hun klinische kenmerken worden beschreven. De 
meest voorkomende cytogenetische afwijkingen zoals die gedetecteerd kunnen 
worden door ‘loss of heterozygosity’ (LOH), ‘comparative genomic hybridisation’ 
(CGH), en ploïdie studies, worden besproken. Bij alle patiënten is chirurgie 
met als doel totale extirpatie, de eerste stap. Voor zowel MBs als ETs is totale 
extirpatie de belangrijkste prognostische marker voor de overleving. Daarna volgen 
verdere therapeutische opties. Voor patiënten met MBs zijn deze gebaseerd op 
een verdeling in ‘gemiddeld risico’ en ‘hoog risico’ groepen. Voor patiënten met 
ETs wordt de rol van chemotherapie (ChT) en radiotherapie (RT) besproken. De 
behandeling van kinderen jonger dan drie jaar met een MB of ET blijft een grote 
uitdaging aangezien RT vermeden moet worden om latere cognitieve en endocriene 
schade te voorkomen. De uitkomst na een recidief MB of ET is slecht, en op dit 
moment zijn er geen standaard behandelingen voorhanden. Ongeveer eenderde 
van de ETs is gelokaliseerd in het ruggenmerg, deze tumoren hebben doorgaans 
een goede prognose.
In hoofdstuk 2 worden genetische veranderingen, gedetecteerd door comparative 
genomic hybridisation (CGH), in MBs beschreven. Tien MB biopten en één MB cel lijn 
werden onderzocht om na te gaan of bepaalde genetische afwijkingen prognostische 
relevantie hebben. Een amplificatie op chromosoom 8q24 kwam overeen met de 
bekende MYCC gen amplificatie van deze cellijn. De amplificatie op 2p21-24 van het 
MYCN gen in twee tumoren werd bevestigd door Southern blot hybridisation en FISH. 
Er kon geen specifiek patroon van genetische veranderingen geassocieerd worden 
met bepaalde klinische karakteristieken van de tumoren. Overige onderzoekers, 
met in totaal 150 MBs vonden eveneens een aspecifiek spectrum van genetische 
afwijkingen. Onze CGH resultaten kwamen niet geheel overeen met de cytogenetische 
analyse, waarschijnlijk ten gevolge van inherente zwakheden van beide procedures. 
Cytogenetische analyse onderzoekt slechts een gedeelte van de tumor cellen. CGH 
detecteert alleen winst of verlies van DNA, dus translocaties, inversies en multiploïdie 
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worden niet gedetecteerd aangezien er voor de procedure gelijke hoeveelheden 
tumor en controle DNA worden gebruikt.
Hoofdstuk 3 is een studie die specifieke genetische subtypes van ET correleert met 
de leeftijd van de patiënt en de lokalisatie van de tumor. Tot dusver hebben klinische 
studies aangetoond dat postoperatieve overleving afhankelijk is van leeftijd, lokalisatie 
van de tumor en de uitgebreidheid van de resectie. Echter, tumor lokalisatie en leeftijd 
zijn gerelateerd. Patiënten met spinale ETs zijn gemiddeld 40 jaar, terwijl daarentegen 
ETs in de fossa posterior voornamelijk voorkomen bij kinderen. Het genoom van 20 
ETs werd middels CGH gescreend op chromosomale afwijkingen. De meest frequent 
gevonden afwijkingen waren verlies van chromosome 22q (75%), 10q (65%), 21 (50%), 
en 16p (50%). Bij de volwassenen hadden de spinale ETs relatief vaak winst van 
chromosome 22, fossa posterior ETs verlies van chromosome 22 en supratentorie’le 
ETs verlies van chromosoom 9. Specifieke chromosomale afwijkingen voor ETs op 
kinder of volwassen leeftijd werd gevonden, met als belangrijkste bevinding winst van 
chromosoom 9 en verlies van chromosoom 6 bij volwassen fossa posterior ETs. De 
genetische achtergrond van ETs is complex en deels verband houdend met tumor 
lokalisatie, histopathologische subtype en leeftijd van de patiënt.
Het verband tussen het aantal genetische afwijkingen (gedetecteerd door CGH en 
ploïdie meting) en de WHO maligniteitsgraad bij ETs werd onderzocht in hoofdstuk 4. 
Wij vonden dat aneuploidy of tetraploidy vaker voorkwam in de groep van myxopapillaire 
ependymomen (mpEs) en minder frequent bij laaggradige ependymale tumoren (lgEs) 
en anaplastische ependymomen (aEs). Tumorweefsel  voor CGH was beschikbaar 
voor ongeveer de helft van de tumoren, en toonden het hoogste aantal genetische 
afwijkingen aan in de mpEs, een lager aantal in lgEs en het laagste aantal in aEs. De 
aEs hadden dus verrassend genoeg minder genetische afwijkingen dan de lgEs. In 
het algemeen behelst maligne progressie een toename van genetische afwijkingen. 
Onze bevindingen suggereren dat lgEs en aEs een ander genetisch patroon hebben. 
Hetzelfde geldt voor mpEs die uitgebreide genetische afwijkingen vertoonden en 
gedefinieerd worden als een graad I maligniteit volgens de WHO classificatie. Deze 
bevindingen bevestigen dat mpEs wezenlijk verschillen van lgEs en aEs op genetisch 
niveau, en dat uitgebreide genetische afwijkingen en aneuploïdie op zich geen tekenen 
zijn van maligne klinisch gedrag, of duiden op een slechte prognose.
Hoofdstuk 5 betreft een studie over de relevantie van insuline-like growth factors 
(IGF’s) in MBs. IGFs zijn kleine polypeptide mitogens die lijken op pro-insuline qua 
structuur. Door binding aan de IGF-I receptor veroorzaken ze groei en anti-apoptotische 
effecten. IGF-I stimuleert het groei hormoon terwijl IGF-II als een autocriene 
groei en motiliteitsfactor werkt gedurende de prenatale groei en ontwikkeling. Het 
expressiepatroon van IGF-l en IGF-ll mRNA in 14 MBs van 12 kinderen en twee 
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volwassenen werd bestudeerd. In alle gevallen vertoonden de tumorcellen volop 
expressie van IGF-l mRNA. Negen tumoren vertoonden IGF-ll expressie. In deze 
tumoren was het hybridisatie signaal bijna uitsluitend gelokaliseerd in een subpopulatie 
van Ki-M1P positieve cellen die werden geïdentificeerd als microglia cellen met een 
‘ramified’ (vertakte) morfologie. Waarschijnlijk wordt tijdens de transformatie van de 
rustende ‘ramified’ naar de amoeboide morfologie (of vice versa) de IGF-II mRNA 
expressie geïnduceerd. De inductie van IGF-II mRNA expressie in deze cellen in 
MBs zou theoretisch gezien mitogene en anti-apoptotische effecten kunnen geven 
op ernaast gelegen tumor cellen, doch de exacte betekenis hiervan behoeft verder 
verduidelijking. Onze bevindingen steunen het idee dat IGF-I en -II betrokken zijn bij de 
ontwikkeling en groei van MBs, en dat het IGF systeem een potentieel therapeutische 
doelwit is.
Hoofdstuk 6 en 7 zijn studies over tumor vascularisatie. Angiogenesis wordt van vitaal 
belang geacht voor de groei van solide tumoren en metastasen, en vormt daarmee 
een doel voor therapie. Het identificeren van het mechanisme van angiogenesis is van 
belang voor het ontwikkelen van anti-angiogenetische therapie. Tumor angiogenesis 
is zowel het resultaat van lokale weefsel condities (vooral hypoxie) als van specifieke 
genetische veranderingen, geaccumuleerd tijdens de oncogenesis.
Hoofdstuk 6 beschrijft een onderzoek naar het verband tussen vasculaire patronen 
en genetische afwijkingen (gedetecteerd door CGH) in subcutaan geïmplanteerde, 
glioblastomas multiforme (GBM) xenograft lijnen. De prognose van patiënten met een 
GBM wordt bepaald door de lokale groei van de tumor. GBMs worden histologisch 
gekarakteriseerd door een zeer intensieve vascularisatie, welke een doelwit kan zijn 
voor nieuwe therapieën. Angiogenesis wordt verondersteld gereguleerd te worden 
door peptides, geproduceerd door tumor cellen in reactie op hypoxie. Anderzijds wordt 
de angiogenesis mogelijk veroorzaakt door specifieke genetische veranderingen 
ontstaan tijdens de oncogenesis. De heterogeniteit van de vasculatuur in GBMs is 
mogelijk gerelateerd aan genetische heterogeniteit binnen een GBM. Om de relatie 
tussen de genetische afwijkingen en de angiogenesis te analyseren werden tien 
GBM xenograften genetisch geanalyseerd middels CGH. De tien xenograft lijnen 
verschilden in vasculair patroon, variërend van goed tot slecht gevasculariseerd. 
In dit model werd een trend gezien waarbij de slecht gevasculariseerde tumoren 
meer genetische afwijkingen hadden. Er was echter geen strikte correlatie tussen 
vasculatuur, groeisnelheid en bepaalde genetische patronen.
Hoofdstuk 7 is een studie over drie-dimensionale (3D) reconstructies van het vaatstelsel 
van de vier histopathologische subtypes van MBs (classic MB, desmoplastisch MB, 
MB with extensive nodularity and advanced neuronal differentitation, large cell/ 
anaplastic MB) en ETs (Low-grade ependymoma (lgE), anaplastic ependymoma (aE), 
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myxopapillary ependymoma (mpE), subependymoma (subE)). Het betreft een pilot 
study waarbij van elk subtype één exemplaar werd onderzocht. 3D reconstructies 
werden verricht door het toepassen van nieuwe beeldanalyse technieken. Daarnaast 
keken we naar vaat aantallen, vaatoppervlakte en vaatperimeter in elk tumor subtype. 
De 3D reconstructies van de vaten van de MBs toonden een vol, dicht patroon van 
irreguliere vaten in de classic en large cell MBs, terwijl in het desmoplastic MB 
en het MB met extensive nodularity, de vaten meer ongelijk verdeeld waren, en 
georganiseerd waren rondom de nodulaire gebieden. Het gemiddelde met betrekking 
tot vaat aantallen, oppervlakte en perimeter kwam overeen met dat van cerebellaire 
cortex en witte stof, met uitzondering van een groter vaatoppervlakte in sommige 
gebieden van het classic en large cell MB. De 3D reconstructies van de vaten van de 
ETs toonden dat lgE minder doch grotere vaten had in vergelijking met aE, terwijl het 
vaatpatroon van mpE complex en irregulier was. Het subE had slecht enkele, doch 
regelmatige vaten. De hoogste waarden voor vaat aantallen, oppervlakte en perimeter 
werden gezien bij het aE, en de laagste waarden bij het subE. 3D vaatreconstructies 
hebben een toegevoegde waarde voor het inzicht in de tumor vasculatuur en zijn een 
waardevol instrument voor toekomstige studies naar angiogenesis.
In hoofdstuk 8, wordt een retrospectieve klinische studie over de waarde van RT voor 
spinale lgEs en mpEs bij volwassenen en kinderen, beschreven. Ziektevrije overleving 
is afhankelijk van lokale controle van de tumor. De waarde van radiotherapie na operatie 
staat nog steeds ter discussie. Het doel van deze retrospectieve studie was om de 
preoperatieve staat, de chirurgische uitkomst en het wel of niet geven radiotherapie 
te onderzoeken, met betrekking tot het vóórkomen van recidieven en neurologische 
uitkomst op langere termijn. Veertig patiënten met een lgEs en 20 patiënten met 
mpEs werden retrospectief onderzocht. Volgens het lokale beleid in verschillende 
ziekenhuizen, werden 14 van de 34 patiënten die een totale resectie ondergingen 
en 20 van de 26 die een incomplete resectie ondergingen, postoperatief bestraald. 
Recidieven traden niet op na een totale resectie, met of zonder radiotherapie. Alle 
patiënten met partieël geresecteerde, niet bestraalde lgEs (n=3) en twee van de drie 
patiënten met partieël geresecteerde, niet bestraalde mpEs kregen een recidief. Bij 
postoperatieve RT na een partieël resectie, hadden drie van de 11 patiënten met 
een lgEs en één van de negen mpE patiënten, een recidief. Onze studie toonde aan 
dat RT alleen zinvol is bij partieel geresecteerde lgEs en mpEs. Lokale controle van 
spinale lgEs en mpEs wordt bereikt door totale resectie. De neurologische uitkomst 
op lange termijn is gerelateerd aan de preoperatieve conditie.
Implicaties voor verdere studie
Voortgang in de behandeling van MBs en ETs kan alleen bereikt worden door een 
stratificatie systeem gebaseerd op prognostische en voorspellende factoren van 
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deze tumoren. Een dergelijke classificatie systeem bestaat uit een combinatie van 
klinische, histopathologische, moleculair genetische en vasculaire kenmerken. Het 
uiteindelijke doel is ‘op maat’ therapie, waarbij de patiënten met de meest agressieve 
tumoren de intensiefste behandeling krijgen, terwijl kinderen met minder agressieve 
tumoren zo effectief mogelijk behandeld worden, doch de late gevolgen van 
intensievere behandelingen bespaard blijven. Het is derhalve van het grootste belang 
om betrouwbare en reproduceerbare prognostische factoren te bepalen. Geleidelijk 
aan komen er meer prognostische en voorspellende factoren beschikbaar die een 
betere verdeling geven in ogenschijnlijke chaotisch heterogene pool van MBs en ETs. 
Recente trials hebben aangetoond dat de histopathologische large cell/ anaplastic 
MB variant geassocieerd is met een slechte prognose [1]. Op moleculair niveau zijn 
verlies van 17p13.3, en/ of MYCC/MYCN amplificatie in MBs geassocieerd met een 
slechtere uitkomst [1]. IGF-I en -II zijn van belang voor tumor groei in MBs, doch hun 
prognostische relevantie moet nog verder onderzocht worden [2]. Tot dus ver zijn 
er geen studies in ETs die betrouwbare moleculair prognostische markers hebben 
opgeleverd [3]. Grotere CGH studies suggereren een associatie tussen winst van 
1q en een slechtere klinische uitkomst [4,5]. De studies in dit proefschrift hebben 
aangetoond dat de histopathologische ET subtypes verschillen met betrekking tot 
genetica, ploïdie, en vasculair patroon. Grotere groepen van ET patiënten zijn nodig 
voor het verder verbeteren van het stratificatie systeem om daarmee behandelingen 
te kunnen optimaliseren.
Een van de manieren om de associatie tussen histopathologische subtypes, groei 
snelheid van de tumoren, vasculatuur en genetische veranderingen verder te 
onderzoeken is het gebruiken van xenograft modellen. Echter, het is zaak om er op 
te letten dat deze modellen zoveel mogelijk de intracerebrale en intracerebellaire 
situatie nabootsen. Met dergelijk modellen kunnen dan de gevolgen van nieuwe 
farmacologische, radiotherapeutische en anti-angiogenetische therapieën op de 
vasculatuur, groei snelheid en recidief kans van de tumoren onderzocht worden.
Het succesvol toepassen van angiogenesis remmers in de klinische praktijk hangt af 
van ons begrip van het angiogenetisch proces [6]. Onze studies hebben het belang 
van toekomstige onderzoek naar de vasculatuur van MBs en ETs onderstreept, 
aangezien specifieke vaatpatronen geassocieerd lijken met bepaalde tumor 
subtypes. Deze bevindingen geven derhalve aanleiding tot toekomstige studies 
naar de interactie van tumoren en bloedvaten op metabool en genetisch niveau. 
3D reconstructies van de vasculatuur met markers voor nieuwe versus preëxistente 
vaten kunnen ons verder helpen bepalen welke vaten een potentieel doelwit zijn voor 
anti-angiogenetische therapie. Dergelijke studies kunnen een voorbereiding zijn voor 
farmacotherapeutische trials gericht op reductie van tumorgroei bij patiënten.
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Tenslotte, de uitkomsten van de studies hier besproken hebben een nieuw licht 
geworpen op pathofysiologie van MBs en ETs, en kunnen dienen als een basis 
voor verder onderzoek naar de moleculaire, genetische en vasculaire kenmerken 
van deze tumoren. Dit zal hopelijk leiden tot meer therapieën op maat, hiermee het 
therapeutisch effect maximaliseren, en de schade aan de cognitieve en lichamelijke 
ontwikkeling van kinderen met dergelijke tumoren zoveel mogelijk beperken.
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